BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hagström H, Nasr P, Ekstedt M, Hammar U, Stål P, Hultcrantz R, Kechagias S. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. Journal of Hepatology 2017;67:1265-73. [DOI: 10.1016/j.jhep.2017.07.027] [Cited by in Crossref: 332] [Cited by in F6Publishing: 309] [Article Influence: 83.0] [Reference Citation Analysis]
Number Citing Articles
1 Schreiner AD, Zhang J, Durkalski-Mauldin V, Livingston S, Marsden J, Bian J, Mauldin PD, Moran WP, Rockey DC. Advanced liver fibrosis and the metabolic syndrome in a primary care setting. Diabetes Metab Res Rev 2021. [PMID: 33759300 DOI: 10.1002/dmrr.3452] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Kong M, Chen X, Xu H, Wenping, Fang M, Xu Y. Hepatocyte-specific deletion of Brg1 alleviates methionine-and-choline-deficient diet (MCD) induced non-alcoholic steatohepatitis in mice. Biochem Biophys Res Commun 2018;503:344-51. [PMID: 29890136 DOI: 10.1016/j.bbrc.2018.06.027] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
3 Dietrich CG, Rau M, Geier A. Screening for nonalcoholic fatty liver disease-when, who and how? World J Gastroenterol 2021; 27(35): 5803-5821 [PMID: 34629804 DOI: 10.3748/wjg.v27.i35.5803] [Reference Citation Analysis]
4 Önnerhag K, Dreja K, Nilsson PM, Lindgren S. Increased mortality in non-alcoholic fatty liver disease with chronic kidney disease is explained by metabolic comorbidities. Clinics and Research in Hepatology and Gastroenterology 2019;43:542-50. [DOI: 10.1016/j.clinre.2019.02.004] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 8.5] [Reference Citation Analysis]
5 Yki-Järvinen H, Luukkonen PK, Hodson L, Moore JB. Dietary carbohydrates and fats in nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 2021. [PMID: 34257427 DOI: 10.1038/s41575-021-00472-y] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
6 Sharpton SR, Schnabl B, Knight R, Loomba R. Current Concepts, Opportunities, and Challenges of Gut Microbiome-Based Personalized Medicine in Nonalcoholic Fatty Liver Disease. Cell Metab 2021;33:21-32. [PMID: 33296678 DOI: 10.1016/j.cmet.2020.11.010] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 12.0] [Reference Citation Analysis]
7 Huber Y, Boyle M, Hallsworth K, Tiniakos D, Straub BK, Labenz C, Ruckes C, Galle PR, Romero-gómez M, Anstee QM, Schattenberg JM. Health-related Quality of Life in Nonalcoholic Fatty Liver Disease Associates With Hepatic Inflammation. Clinical Gastroenterology and Hepatology 2019;17:2085-2092.e1. [DOI: 10.1016/j.cgh.2018.12.016] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 19.0] [Reference Citation Analysis]
8 Ipsen DH, Skat-rørdam J, Tsamouri MM, Latta M, Lykkesfeldt J, Tveden-nyborg P. Molecular drivers of non-alcoholic steatohepatitis are sustained in mild-to-late fibrosis progression in a guinea pig model. Mol Genet Genomics 2019;294:649-61. [DOI: 10.1007/s00438-019-01537-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
9 Kasper P, Martin A, Lang S, Kütting F, Goeser T, Demir M, Steffen HM. NAFLD and cardiovascular diseases: a clinical review. Clin Res Cardiol 2021;110:921-37. [PMID: 32696080 DOI: 10.1007/s00392-020-01709-7] [Cited by in Crossref: 22] [Cited by in F6Publishing: 27] [Article Influence: 22.0] [Reference Citation Analysis]
10 Wu S, Meng X, Jiang X, Wu Y, Zhai S, Wang X, Liu Y, Zhang J, Zhao X, Zhou Y, Bu W, Yao Z. Harnessing X-Ray Energy-Dependent Attenuation of Bismuth-Based Nanoprobes for Accurate Diagnosis of Liver Fibrosis. Adv Sci (Weinh) 2021;8:e2002548. [PMID: 34105274 DOI: 10.1002/advs.202002548] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Lei P, Jiao J, Li H, Wang P, Duan Q, Liu J, Zhou S, Wei Q, Wang X. NAFLD evaluation: Which is more appropriate, multislice computed tomography or ultrasound real-time shear wave elastography? J Xray Sci Technol 2019;27:871-83. [PMID: 31256111 DOI: 10.3233/XST-190502] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 [DOI: 10.1101/2020.09.23.20200535] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
13 Shah RA, Alkhouri N, Kowdley KV. Emerging drugs for the treatment of non-alcoholic steatohepatitis: a focused review of farnesoid X receptor agonists. Expert Opinion on Emerging Drugs 2020;25:251-60. [DOI: 10.1080/14728214.2020.1796968] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
14 Schonmann Y, Yeshua H, Bentov I, Zelber-Sagi S. Liver fibrosis marker is an independent predictor of cardiovascular morbidity and mortality in the general population. Dig Liver Dis. 2021;53:79-85. [PMID: 33144054 DOI: 10.1016/j.dld.2020.10.014] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
15 Rinella ME, Tacke F, Sanyal AJ, Anstee QM; participants of the AASLD/EASL Workshop. Report on the AASLD/EASL Joint Workshop on Clinical Trial Endpoints in NAFLD. Hepatology. 2019;70:1424-1436. [PMID: 31287572 DOI: 10.1002/hep.30782] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 18.0] [Reference Citation Analysis]
16 Zhou JH, Cai JJ, She ZG, Li HL. Noninvasive evaluation of nonalcoholic fatty liver disease: Current evidence and practice. World J Gastroenterol 2019; 25(11): 1307-1326 [PMID: 30918425 DOI: 10.3748/wjg.v25.i11.1307] [Cited by in CrossRef: 63] [Cited by in F6Publishing: 52] [Article Influence: 31.5] [Reference Citation Analysis]
17 Sookoian S, Flichman D, Garaycoechea ME, San Martino J, Castaño GO, Pirola CJ. Metastasis-associated lung adenocarcinoma transcript 1 as a common molecular driver in the pathogenesis of nonalcoholic steatohepatitis and chronic immune-mediated liver damage. Hepatol Commun 2018;2:654-65. [PMID: 29881817 DOI: 10.1002/hep4.1184] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
18 Tateishi R, Matsumura T, Okanoue T, Shima T, Uchino K, Fujiwara N, Senokuchi T, Kon K, Sasako T, Taniai M, Kawaguchi T, Inoue H, Watada H, Kubota N, Shimano H, Kaneko S, Hashimoto E, Watanabe S, Shiota G, Ueki K, Kashiwabara K, Matsuyama Y, Tanaka H, Kasuga M, Araki E, Koike K; LUCID study investigators. Hepatocellular carcinoma development in diabetic patients: a nationwide survey in Japan. J Gastroenterol 2021;56:261-73. [PMID: 33427937 DOI: 10.1007/s00535-020-01754-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
19 Bzowej NH. Nonalcoholic steatohepatitis: the new frontier for liver transplantation. Curr Opin Organ Transplant. 2018;23:169-174. [PMID: 29356708 DOI: 10.1097/mot.0000000000000502] [Cited by in Crossref: 18] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
20 Goldner D, Lavine JE. Nonalcoholic Fatty Liver Disease in Children: Unique Considerations and Challenges. Gastroenterology. 2020;158:1967-1983.e1. [PMID: 32201176 DOI: 10.1053/j.gastro.2020.01.048] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 19.0] [Reference Citation Analysis]
21 Kazankov K, Rosso C, Younes R, Armandi A, Hagström H, Møller HJ, Stål P, Bugianesi E, Grønbæk H. Macrophage Markers Do Not Add to the Prediction of Liver Fibrosis by Transient Elastography in Patients With Metabolic Associated Fatty Liver Disease. Front Med (Lausanne) 2020;7:616212. [PMID: 33392234 DOI: 10.3389/fmed.2020.616212] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Castera L. Non-invasive tests for liver fibrosis in NAFLD: Creating pathways between primary healthcare and liver clinics. Liver Int 2020;40 Suppl 1:77-81. [PMID: 32077617 DOI: 10.1111/liv.14347] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 14.0] [Reference Citation Analysis]
23 Forlano R, Mullish BH, Nathwani R, Dhar A, Thursz MR, Manousou P. Non-Alcoholic Fatty Liver Disease and Vascular Disease. CVP 2020;19:269-79. [DOI: 10.2174/1570161118666200318103001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
24 Lemoine M, Assoumou L, De Wit S, Girard PM, Valantin MA, Katlama C, Necsoi C, Campa P, Huefner AD, Schulze Zur Wiesch J, Rougier H, Bastard JP, Stocker H, Mauss S, Serfaty L, Ratziu V, Menu Y, Schlue J, Behrens G, Bedossa P, Capeau J, Ingiliz P, Costagliola D; ANRS-ECHAM Group. Diagnostic Accuracy of Noninvasive Markers of Steatosis, NASH, and Liver Fibrosis in HIV-Monoinfected Individuals at Risk of Nonalcoholic Fatty Liver Disease (NAFLD): Results From the ECHAM Study. J Acquir Immune Defic Syndr 2019;80:e86-94. [PMID: 30570529 DOI: 10.1097/QAI.0000000000001936] [Cited by in Crossref: 24] [Cited by in F6Publishing: 7] [Article Influence: 12.0] [Reference Citation Analysis]
25 D’amico G, Perricone G. Prediction of Decompensation in Patients with Compensated Cirrhosis: Does Etiology Matter? Curr Hepatology Rep 2019;18:144-56. [DOI: 10.1007/s11901-019-00473-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
26 Chen PC, Kao WY, Cheng YL, Wang YJ, Hou MC, Wu JC, Su CW. The correlation between fatty liver disease and chronic kidney disease. J Formos Med Assoc. 2020;119:42-50. [PMID: 30876789 DOI: 10.1016/j.jfma.2019.02.010] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
27 Tillman EJ, Rolph T. FGF21: An Emerging Therapeutic Target for Non-Alcoholic Steatohepatitis and Related Metabolic Diseases. Front Endocrinol (Lausanne) 2020;11:601290. [PMID: 33381084 DOI: 10.3389/fendo.2020.601290] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 10.0] [Reference Citation Analysis]
28 Targher G, Corey KE, Byrne CD. NAFLD, and cardiovascular and cardiac diseases: Factors influencing risk, prediction and treatment. Diabetes Metab 2021;47:101215. [PMID: 33296704 DOI: 10.1016/j.diabet.2020.101215] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
29 Fujii H, Imajo K, Yoneda M, Nakahara T, Hyogo H, Takahashi H, Hara T, Tanaka S, Sumida Y, Eguchi Y, Chayama K, Nakajima A, Nishimoto N, Kawada N; Japan Study Group of Nonalcoholic Fatty Liver Disease. HOMA-IR: An independent predictor of advanced liver fibrosis in nondiabetic non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2019;34:1390-5. [PMID: 30600551 DOI: 10.1111/jgh.14595] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 12.5] [Reference Citation Analysis]
30 Lin B, Ma Y, Wu S, Liu Y, Liu L, Wu L. Novel Serum Biomarkers for Noninvasive Diagnosis and Screening of Nonalcoholic Fatty Liver Disease-Related Hepatic Fibrosis. OMICS 2019;23:181-9. [PMID: 30932742 DOI: 10.1089/omi.2019.0035] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
31 Bayrak M. Non-invasive diagnosis of nonalcoholic fatty liver disease: impact of age and other risk factors. Aging Male 2020;23:1275-82. [PMID: 32396414 DOI: 10.1080/13685538.2020.1763293] [Reference Citation Analysis]
32 Ampuero J, Pais R, Aller R, Gallego-Durán R, Crespo J, García-Monzón C, Boursier J, Vilar E, Petta S, Zheng MH, Escudero D, Calleja JL, Aspichueta P, Diago M, Rosales JM, Caballería J, Gómez-Camarero J, Lo Iacono O, Benlloch S, Albillos A, Turnes J, Banales JM, Ratziu V, Romero-Gómez M; HEPAmet Registry. Development and Validation of Hepamet Fibrosis Scoring System-A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis. Clin Gastroenterol Hepatol 2020;18:216-225.e5. [PMID: 31195161 DOI: 10.1016/j.cgh.2019.05.051] [Cited by in Crossref: 36] [Cited by in F6Publishing: 27] [Article Influence: 18.0] [Reference Citation Analysis]
33 Ratziu V, Ghabril M, Romero-Gomez M, Svegliati-Baroni G. Recommendations for Management and Treatment of Nonalcoholic Steatohepatitis. Transplantation 2019;103:28-38. [PMID: 30300289 DOI: 10.1097/TP.0000000000002483] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 5.5] [Reference Citation Analysis]
34 Bosch J, Gracia-Sancho J, Abraldes JG. Cirrhosis as new indication for statins. Gut 2020;69:953-62. [PMID: 32139553 DOI: 10.1136/gutjnl-2019-318237] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 21.0] [Reference Citation Analysis]
35 Chen Z, Cao Y, Zhang Y, Qiao Y. A Novel Discovery: Holistic Efficacy at the Special Organ Level of Pungent Flavored Compounds from Pungent Traditional Chinese Medicine. Int J Mol Sci 2019;20:E752. [PMID: 30754631 DOI: 10.3390/ijms20030752] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
36 Urata N, Kawanaka M, Nishino K, Ishii K, Tanikawa T, Suehiro M, Sasai T, Haruma K, Kawamoto H, Nakamura J, Manabe N, Kamada T. Fatty Liver, and Not Visceral Fat, Is More Associated with Liver Fibrosis and Diabetes in Non-Obese Japanese Individuals: A Cross-Sectional Study. Life (Basel) 2020;10:E175. [PMID: 32899741 DOI: 10.3390/life10090175] [Reference Citation Analysis]
37 Ibrahim SH, Malhi H. A Molecular Signature of Mouse NASH: A Step Closer to a Human Predictive Biomarker? Cell Mol Gastroenterol Hepatol 2018;5:65-6. [PMID: 29276752 DOI: 10.1016/j.jcmgh.2017.10.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
38 Nasr P, Ignatova S, Kechagias S, Ekstedt M. Natural history of nonalcoholic fatty liver disease: A prospective follow-up study with serial biopsies. Hepatol Commun. 2018;2:199-210. [PMID: 29404527 DOI: 10.1002/hep4.1134] [Cited by in Crossref: 48] [Cited by in F6Publishing: 47] [Article Influence: 12.0] [Reference Citation Analysis]
39 Petzold G, Bremer SCB, Knoop RF, Amanzada A, Raddatz D, Ellenrieder V, Ströbel P, Kunsch S, Neesse A. Noninvasive assessment of liver fibrosis in a real-world cohort of patients with known or suspected chronic liver disease using 2D-shear wave elastography. Eur J Gastroenterol Hepatol 2020;32:1559-65. [PMID: 31922976 DOI: 10.1097/MEG.0000000000001675] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
40 Hydes T, Brown E, Hamid A, Bateman AC, Cuthbertson DJ. Current and Emerging Biomarkers and Imaging Modalities for Nonalcoholic Fatty Liver Disease: Clinical and Research Applications. Clin Ther 2021:S0149-2918(21)00256-3. [PMID: 34400007 DOI: 10.1016/j.clinthera.2021.07.012] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
41 Younossi ZM. Non-alcoholic fatty liver disease – A global public health perspective. Journal of Hepatology 2019;70:531-44. [DOI: 10.1016/j.jhep.2018.10.033] [Cited by in Crossref: 452] [Cited by in F6Publishing: 433] [Article Influence: 226.0] [Reference Citation Analysis]
42 Franks PW, Melén E, Friedman M, Sundström J, Kockum I, Klareskog L, Almqvist C, Bergen SE, Czene K, Hägg S, Hall P, Johnell K, Malarstig A, Catrina A, Hagström H, Benson M, Gustav Smith J, Gomez MF, Orho-Melander M, Jacobsson B, Halfvarson J, Repsilber D, Oresic M, Jern C, Melin B, Ohlsson C, Fall T, Rönnblom L, Wadelius M, Nordmark G, Johansson Å, Rosenquist R, Sullivan PF. Technological readiness and implementation of genomic-driven precision medicine for complex diseases. J Intern Med 2021;290:602-20. [PMID: 34213793 DOI: 10.1111/joim.13330] [Reference Citation Analysis]
43 Tada T, Toyoda H, Sone Y, Yasuda S, Miyake N, Kumada T, Tanaka J. Type 2 diabetes mellitus: A risk factor for progression of liver fibrosis in middle‐aged patients with non‐alcoholic fatty liver disease. Journal of Gastroenterology and Hepatology 2019;34:2011-8. [DOI: 10.1111/jgh.14734] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
44 Polyzos SA, Kountouras J, Mantzoros CS. Obeticholic acid for the treatment of nonalcoholic steatohepatitis: Expectations and concerns. Metabolism 2020;104:154144. [DOI: 10.1016/j.metabol.2020.154144] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 10.0] [Reference Citation Analysis]
45 Kannt A, Madsen AN, Kammermeier C, Elvert R, Klöckener T, Bossart M, Haack T, Evers A, Lorenz K, Hennerici W, Rocher C, Böcskei Z, Guillemot J, Mikol V, Pattou F, Staels B, Wagner M. Incretin combination therapy for the treatment of non‐alcoholic steatohepatitis. Diabetes Obes Metab 2020;22:1328-38. [DOI: 10.1111/dom.14035] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
46 Pedrosa M, Seyedkazemi S, Francque S, Sanyal A, Rinella M, Charlton M, Loomba R, Ratziu V, Kochuparampil J, Fischer L, Vaidyanathan S, Anstee QM. A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial. Contemporary Clinical Trials 2020;88:105889. [DOI: 10.1016/j.cct.2019.105889] [Cited by in Crossref: 29] [Cited by in F6Publishing: 33] [Article Influence: 29.0] [Reference Citation Analysis]
47 Honda Y, Yoneda M, Imajo K, Nakajima A. Elastography Techniques for the Assessment of Liver Fibrosis in Non-Alcoholic Fatty Liver Disease.Int J Mol Sci. 2020;21. [PMID: 32516937 DOI: 10.3390/ijms21114039] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 9.0] [Reference Citation Analysis]
48 Younossi ZM, Ratziu V, Loomba R, Rinella M, Anstee QM, Goodman Z, Bedossa P, Geier A, Beckebaum S, Newsome PN, Sheridan D, Sheikh MY, Trotter J, Knapple W, Lawitz E, Abdelmalek MF, Kowdley KV, Montano-Loza AJ, Boursier J, Mathurin P, Bugianesi E, Mazzella G, Olveira A, Cortez-Pinto H, Graupera I, Orr D, Gluud LL, Dufour JF, Shapiro D, Campagna J, Zaru L, MacConell L, Shringarpure R, Harrison S, Sanyal AJ; REGENERATE Study Investigators. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2019;394:2184-2196. [PMID: 31813633 DOI: 10.1016/s0140-6736(19)33041-7] [Cited by in Crossref: 296] [Cited by in F6Publishing: 151] [Article Influence: 148.0] [Reference Citation Analysis]
49 Itoh Y, Seko Y, Shima T, Nakajima T, Mizuno K, Kawamura Y, Akuta N, Ito K, Kawanaka M, Hiramatsu A, Sakamoto M, Harada K, Goto Y, Nakayama T, Kumada H, Okanoue T. Accuracy of non-invasive scoring systems for diagnosing non-alcoholic steatohepatitis-related fibrosis: Multicenter validation study. Hepatol Res. 2018;48:1099-1107. [PMID: 29974624 DOI: 10.1111/hepr.13226] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
50 Han MAT, Vipani A, Noureddin N, Ramirez K, Gornbein J, Saouaf R, Baniesh N, Cummings-John O, Okubote T, Setiawan VW, Rotman Y, Loomba R, Alkhouri N, Noureddin M. MR elastography-based liver fibrosis correlates with liver events in nonalcoholic fatty liver patients: A multicenter study. Liver Int 2020;40:2242-51. [PMID: 32652744 DOI: 10.1111/liv.14593] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
51 Hirose S, Matsumoto K, Tatemichi M, Tsuruya K, Anzai K, Arase Y, Shiraishi K, Suzuki M, Ieda S, Kagawa T. Nineteen-year prognosis in Japanese patients with biopsy-proven nonalcoholic fatty liver disease: Lean versus overweight patients. PLoS One 2020;15:e0241770. [PMID: 33186403 DOI: 10.1371/journal.pone.0241770] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
52 Younes R, Caviglia GP, Govaere O, Rosso C, Armandi A, Sanavia T, Pennisi G, Liguori A, Francione P, Gallego-Durán R, Ampuero J, Garcia Blanco MJ, Aller R, Tiniakos D, Burt A, David E, Vecchio FM, Maggioni M, Cabibi D, Pareja MJ, Zaki MYW, Grieco A, Fracanzani AL, Valenti L, Miele L, Fariselli P, Petta S, Romero-Gomez M, Anstee QM, Bugianesi E. Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease. J Hepatol 2021:S0168-8278(21)00343-3. [PMID: 34090928 DOI: 10.1016/j.jhep.2021.05.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
53 Mikolasevic I, Lukenda Zanko V, Jakopcic I, Domislovic V, Mijic A, Stevanovic T, Delija B, Bokun T, Dinjar Kujundzic P, Ostojic A, Filipec Kanizaj T, Grgurevic I, Krznaric Z, Stimac D, Targher G. Prospective evaluation of non-alcoholic fatty liver disease by elastographic methods of liver steatosis and fibrosis; controlled attenuation parameter and liver stiffness measurements. J Diabetes Complications 2020;34:107512. [PMID: 31882273 DOI: 10.1016/j.jdiacomp.2019.107512] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
54 Choi HSJ, Brouwer WP, Zanjir WMR, de Man RA, Feld JJ, Hansen BE, Janssen HLA, Patel K. Nonalcoholic Steatohepatitis Is Associated With Liver-Related Outcomes and All-Cause Mortality in Chronic Hepatitis B. Hepatology. 2020;71:539-548. [PMID: 31309589 DOI: 10.1002/hep.30857] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 17.0] [Reference Citation Analysis]
55 Alferink LJM, Kiefte-de Jong JC, Erler NS, de Knegt RJ, Hoorn EJ, Ikram MA, Janssen HLA, Metselaar HJ, Franco OH, Darwish Murad S. Diet-Dependent Acid Load-The Missing Link Between an Animal Protein-Rich Diet and Nonalcoholic Fatty Liver Disease? J Clin Endocrinol Metab 2019;104:6325-37. [PMID: 30977830 DOI: 10.1210/jc.2018-02792] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
56 Eguchi Y, Wong G, Akhtar O, Sumida Y. Non‐invasive diagnosis of non‐alcoholic steatohepatitis and advanced fibrosis in Japan: A targeted literature review. Hepatol Res 2020;50:645-55. [DOI: 10.1111/hepr.13502] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
57 Jensen T, Wieland A, Cree-Green M, Nadeau K, Sullivan S. Clinical workup of fatty liver for the primary care provider. Postgrad Med 2019;131:19-30. [PMID: 30496690 DOI: 10.1080/00325481.2019.1546532] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
58 Castellana M, Donghia R, Guerra V, Procino F, Castellana F, Zupo R, Lampignano L, Sardone R, De Pergola G, Romanelli F, Trimboli P, Giannelli G. Fibrosis-4 Index vs Nonalcoholic Fatty Liver Disease Fibrosis Score in Identifying Advanced Fibrosis in Subjects With Nonalcoholic Fatty Liver Disease: A Meta-Analysis. Am J Gastroenterol 2021;116:1833-41. [PMID: 34160377 DOI: 10.14309/ajg.0000000000001337] [Reference Citation Analysis]
59 Jiao J, Kwan SY, Sabotta CM, Tanaka H, Veillon L, Warmoes MO, Lorenzi PL, Wang Y, Wei P, Hawk ET, Almeda JL, McCormick JB, Fisher-Hoch SP, Beretta L. Circulating Fatty Acids Associated with Advanced Liver Fibrosis and Hepatocellular Carcinoma in South Texas Hispanics. Cancer Epidemiol Biomarkers Prev 2021;30:1643-51. [PMID: 34155064 DOI: 10.1158/1055-9965.EPI-21-0183] [Reference Citation Analysis]
60 Koeckerling D, Tomlinson JW, Cobbold JF. Fighting liver fat. Endocr Connect 2020;9:R173-86. [PMID: 32621584 DOI: 10.1530/EC-20-0174] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
61 Cheung A, Neuschwander-Tetri BA, Kleiner DE, Schabel E, Rinella M, Harrison S, Ratziu V, Sanyal AJ, Loomba R, Jeannin Megnien S, Torstenson R, Miller V; Liver Forum Case Definitions Working Group. Defining Improvement in Nonalcoholic Steatohepatitis for Treatment Trial Endpoints: Recommendations From the Liver Forum. Hepatology 2019;70:1841-55. [PMID: 31034092 DOI: 10.1002/hep.30672] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 40.0] [Reference Citation Analysis]
62 Wu YL, Kumar R, Wang MF, Singh M, Huang JF, Zhu YY, Lin S. Validation of conventional non-invasive fibrosis scoring systems in patients with metabolic associated fatty liver disease. World J Gastroenterol 2021; 27(34): 5753-5763 [PMID: 34629799 DOI: 10.3748/wjg.v27.i34.5753] [Reference Citation Analysis]
63 Akuta N, Kawamura Y, Arase Y, Saitoh S, Fujiyama S, Sezaki H, Hosaka T, Kobayashi M, Kobayashi M, Suzuki Y, Suzuki F, Ikeda K, Kumada H. Hepatocellular carcinoma is the most common liver-related complication in patients with histopathologically-confirmed NAFLD in Japan. BMC Gastroenterol 2018;18:165. [PMID: 30400829 DOI: 10.1186/s12876-018-0900-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 3.7] [Reference Citation Analysis]
64 Önnerhag K, Hartman H, Nilsson PM, Lindgren S. Non-invasive fibrosis scoring systems can predict future metabolic complications and overall mortality in non-alcoholic fatty liver disease (NAFLD). Scandinavian Journal of Gastroenterology 2019;54:328-34. [DOI: 10.1080/00365521.2019.1583366] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 10.0] [Reference Citation Analysis]
65 Cheung A, Figueredo C, Rinella ME. Nonalcoholic Fatty Liver Disease: Identification and Management of High-Risk Patients. Am J Gastroenterol 2019;114:579-90. [PMID: 30839326 DOI: 10.14309/ajg.0000000000000058] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 12.0] [Reference Citation Analysis]
66 Petta S, Di Marco V, Pipitone RM, Grimaudo S, Buscemi C, Craxì A, Buscemi S. Prevalence and severity of nonalcoholic fatty liver disease by transient elastography: Genetic and metabolic risk factors in a general population. Liver Int 2018;38:2060-8. [DOI: 10.1111/liv.13743] [Cited by in Crossref: 32] [Cited by in F6Publishing: 25] [Article Influence: 10.7] [Reference Citation Analysis]
67 Schuster S, Cabrera D, Arrese M, Feldstein AE. Triggering and resolution of inflammation in NASH. Nat Rev Gastroenterol Hepatol. 2018;15:349-364. [PMID: 29740166 DOI: 10.1038/s41575-018-0009-6] [Cited by in Crossref: 197] [Cited by in F6Publishing: 196] [Article Influence: 98.5] [Reference Citation Analysis]
68 Noureddin N, Noureddin M, Singh A, Alkhouri N. Progression of Nonalcoholic Fatty Liver Disease-Associated Fibrosis in a Large Cohort of Patients with Type 2 Diabetes. Dig Dis Sci 2021. [PMID: 33779880 DOI: 10.1007/s10620-021-06955-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
69 Arai T, Atsukawa M, Tsubota A, Mikami S, Ono H, Kawano T, Yoshida Y, Tanabe T, Okubo T, Hayama K, Nakagawa-Iwashita A, Itokawa N, Kondo C, Kaneko K, Emoto N, Nagao M, Inagaki K, Fukuda I, Sugihara H, Iwakiri K. Effect of sodium-glucose cotransporter 2 inhibitor in patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus: a propensity score-matched analysis of real-world data. Ther Adv Endocrinol Metab 2021;12:20420188211000243. [PMID: 33815743 DOI: 10.1177/20420188211000243] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
70 [DOI: 10.1101/2021.04.08.21255106] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
71 Gege C, Hambruch E, Hambruch N, Kinzel O, Kremoser C. Nonsteroidal FXR Ligands: Current Status and Clinical Applications. In: Fiorucci S, Distrutti E, editors. Bile Acids and Their Receptors. Cham: Springer International Publishing; 2019. pp. 167-205. [DOI: 10.1007/164_2019_232] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 12.0] [Reference Citation Analysis]
72 Daniels SJ, Leeming DJ, Detlefsen S, Bruun MF, Hjuler ST, Henriksen K, Hein P, Karsdal MA, Brockbank S, Cruwys S. Biochemical and histological characterisation of an experimental rodent model of non-alcoholic steatohepatitis – Effects of a peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist and a glucagon-like peptide-1 analogue. Biomedicine & Pharmacotherapy 2019;111:926-33. [DOI: 10.1016/j.biopha.2018.12.130] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
73 Shima T, Ohtakaki Y, Kikuchi H, Uchino H, Isomura M, Aoyagi K, Oya H, Katayama T, Mitsumoto Y, Mizuno M, Umemura A, Yamaguchi K, Itoh Y, Okanoue T. A novel rapid immunoassay of serum type IV collagen 7S for the diagnosis of fibrosis stage of nonalcoholic fatty liver diseases. Hepatol Res 2021;51:263-76. [PMID: 33350036 DOI: 10.1111/hepr.13605] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
74 Li W, Alazawi W. Non-alcoholic fatty liver disease. Clin Med (Lond) 2020;20:509-12. [PMID: 32934047 DOI: 10.7861/clinmed.2020-0696] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
75 Holmer M, Lindqvist C, Petersson S, Moshtaghi-Svensson J, Tillander V, Brismar TB, Hagström H, Stål P. Treatment of NAFLD with intermittent calorie restriction or low-carb high-fat diet - a randomised controlled trial. JHEP Rep 2021;3:100256. [PMID: 33898960 DOI: 10.1016/j.jhepr.2021.100256] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
76 Smeuninx B, Boslem E, Febbraio MA. Current and Future Treatments in the Fight Against Non-Alcoholic Fatty Liver Disease. Cancers (Basel) 2020;12:E1714. [PMID: 32605253 DOI: 10.3390/cancers12071714] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
77 Kogachi S, Noureddin M. Noninvasive Evaluation for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Clin Ther 2021;43:455-72. [PMID: 33581876 DOI: 10.1016/j.clinthera.2021.01.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
78 Castera L, Friedrich-Rust M, Loomba R. Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2019;156:1264-1281.e4. [PMID: 30660725 DOI: 10.1053/j.gastro.2018.12.036] [Cited by in Crossref: 310] [Cited by in F6Publishing: 296] [Article Influence: 155.0] [Reference Citation Analysis]
79 Clearfield E, Miller V, Nadglowski J, Barradas K, Al Naber J, Sanyal AJ, Neuschwander-Tetri BA, Messner DA; coreNASH Panel. coreNASH: Multi-stakeholder Consensus on Core Outcomes for Decision Making About Nonalcoholic Steatohepatitis Treatment. Hepatol Commun 2021;5:774-85. [PMID: 34027268 DOI: 10.1002/hep4.1678] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
80 Sanyal AJ. Past, present and future perspectives in nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. 2019;16:377-386. [PMID: 31024089 DOI: 10.1038/s41575-019-0144-8] [Cited by in Crossref: 144] [Cited by in F6Publishing: 132] [Article Influence: 72.0] [Reference Citation Analysis]
81 Mikolasevic I, Domislovic V, Turk Wensveen T, Delija B, Klapan M, Juric T, Lukic A, Mijic A, Skenderevic N, Puz P, Ostojic A, Krznaric Z, Radic-Kristo D, Filipec Kanizaj T, Stimac D. Screening for nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus using transient elastography - a prospective, cross sectional study. Eur J Intern Med 2020;82:68-75. [PMID: 32839076 DOI: 10.1016/j.ejim.2020.08.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
82 Chen L, Huang W, Wang L, Zhang Z, Zhang F, Zheng S, Kong D. The effects of epigenetic modification on the occurrence and progression of liver diseases and the involved mechanism. Expert Rev Gastroenterol Hepatol 2020;14:259-70. [PMID: 32124651 DOI: 10.1080/17474124.2020.1736042] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
83 Scragg J, Avery L, Cassidy S, Taylor G, Haigh L, Boyle M, Trenell MI, Anstee QM, McPherson S, Hallsworth K. Feasibility of a Very Low Calorie Diet to Achieve a Sustainable 10% Weight Loss in Patients With Nonalcoholic Fatty Liver Disease. Clin Transl Gastroenterol 2020;11:e00231. [PMID: 33094956 DOI: 10.14309/ctg.0000000000000231] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
84 Ratziu V. A critical review of endpoints for non-cirrhotic NASH therapeutic trials. Journal of Hepatology 2018;68:353-61. [DOI: 10.1016/j.jhep.2017.12.001] [Cited by in Crossref: 29] [Cited by in F6Publishing: 33] [Article Influence: 9.7] [Reference Citation Analysis]
85 Schattenberg JM, Ekstedt M. Assessing the disease burden of non-alcoholic fatty liver disease in the real world - big data and big numbers. BMC Med 2019;17:123. [PMID: 31269936 DOI: 10.1186/s12916-019-1357-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
86 Wang ZH, Zheng KI, Wang XD, Qiao J, Li YY, Zhang L, Zheng MH, Wu J. LC-MS-based lipidomic analysis in distinguishing patients with nonalcoholic steatohepatitis from nonalcoholic fatty liver. Hepatobiliary Pancreat Dis Int 2021:S1499-3872(21)00115-6. [PMID: 34256994 DOI: 10.1016/j.hbpd.2021.05.008] [Reference Citation Analysis]
87 Rivera-Esteban J, Armandi A, Augustin S, Bugianesi E. Outcomes and potential surrogate markers for future clinical trials of non-alcoholic steatohepatitis cirrhosis. Liver Int 2021;41:1999-2008. [PMID: 34242466 DOI: 10.1111/liv.15013] [Reference Citation Analysis]
88 Jin X, Gao J, Zheng R, Yu M, Ren Y, Yan T, Huang Y, Li Y. Antagonizing circRNA_002581-miR-122-CPEB1 axis alleviates NASH through restoring PTEN-AMPK-mTOR pathway regulated autophagy. Cell Death Dis 2020;11:123. [PMID: 32054840 DOI: 10.1038/s41419-020-2293-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
89 Boland ML, Oldham S, Boland BB, Will S, Lapointe JM, Guionaud S, Rhodes CJ, Trevaskis JL. Nonalcoholic steatohepatitis severity is defined by a failure in compensatory antioxidant capacity in the setting of mitochondrial dysfunction. World J Gastroenterol 2018; 24(16): 1748-1765 [PMID: 29713129 DOI: 10.3748/wjg.v24.i16.1748] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 23] [Article Influence: 8.0] [Reference Citation Analysis]
90 Kawanaka M, Nishino K, Ishii K, Tanikawa T, Urata N, Suehiro M, Sasai T, Haruma K, Kawamoto H. Combination of type IV collagen 7S, albumin concentrations, and platelet count predicts prognosis of non-alcoholic fatty liver disease. World J Hepatol 2021; 13(5): 571-583 [PMID: 34131471 DOI: 10.4254/wjh.v13.i5.571] [Reference Citation Analysis]
91 Itier R, Guillaume M, Ricci JE, Roubille F, Delarche N, Picard F, Galinier M, Roncalli J. Non-alcoholic fatty liver disease and heart failure with preserved ejection fraction: from pathophysiology to practical issues. ESC Heart Fail 2021;8:789-98. [PMID: 33534958 DOI: 10.1002/ehf2.13222] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
92 Wei G, An P, Vaid KA, Nasser I, Huang P, Tan L, Zhao S, Schuppan D, Popov YV. Comparison of murine steatohepatitis models identifies a dietary intervention with robust fibrosis, ductular reaction, and rapid progression to cirrhosis and cancer. Am J Physiol Gastrointest Liver Physiol 2020;318:G174-88. [PMID: 31630534 DOI: 10.1152/ajpgi.00041.2019] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
93 Hartl L, Elias J, Prager G, Reiberger T, Unger LW. Individualized treatment options for patients with non-cirrhotic and cirrhotic liver disease. World J Gastroenterol 2021; 27(19): 2281-2298 [PMID: 34040322 DOI: 10.3748/wjg.v27.i19.2281] [Reference Citation Analysis]
94 Asgharpour A, Dinani A, Friedman SL. Basic science to clinical trials in non-alcoholic fatty liver disease and alcohol-related liver disease: collaboration with industry. Transl Gastroenterol Hepatol 2021;6:5. [PMID: 33409399 DOI: 10.21037/tgh.2020.01.04] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
95 Petroff D, Bätz O, Jedrysiak K, Kramer J, Berg T, Wiegand J. Fibrosis-4 (FIB-4) score at the primary care level: an analysis of over 160 000 blood samples. Gut 2021;70:219-21. [PMID: 32245907 DOI: 10.1136/gutjnl-2020-320995] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
96 Arai T, Atsukawa M, Tsubota A, Kato K, Abe H, Ono H, Kawano T, Yoshida Y, Tanabe T, Okubo T, Hayama K, Nakagawa-Iwashita A, Itokawa N, Kondo C, Kaneko K, Emoto N, Nagao M, Inagaki K, Fukuda I, Sugihara H, Iwakiri K. Liver fibrosis is associated with carotid atherosclerosis in patients with liver biopsy-proven nonalcoholic fatty liver disease. Sci Rep 2021;11:15938. [PMID: 34354193 DOI: 10.1038/s41598-021-95581-8] [Reference Citation Analysis]
97 Sumida Y, Yoneda M. Current and future pharmacological therapies for NAFLD/NASH. J Gastroenterol. 2018;53:362-376. [PMID: 29247356 DOI: 10.1007/s00535-017-1415-1] [Cited by in Crossref: 227] [Cited by in F6Publishing: 214] [Article Influence: 56.8] [Reference Citation Analysis]
98 Rockey DC, Friedman SL. Fibrosis Regression After Eradication of Hepatitis C Virus: From Bench to Bedside. Gastroenterology 2021;160:1502-1520.e1. [PMID: 33529675 DOI: 10.1053/j.gastro.2020.09.065] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
99 Rau M, Geier A. An update on drug development for the treatment of nonalcoholic fatty liver disease - from ongoing clinical trials to future therapy.Expert Rev Clin Pharmacol. 2021;14:333-340. [PMID: 33535836 DOI: 10.1080/17512433.2021.1884068] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
100 Xu XL, Jiang LS, Wu CS, Pan LY, Lou ZQ, Peng CT, Dong Y, Ruan B. The role of fibrosis index FIB-4 in predicting liver fibrosis stage and clinical prognosis: A diagnostic or screening tool? J Formos Med Assoc 2021:S0929-6646(21)00344-2. [PMID: 34325952 DOI: 10.1016/j.jfma.2021.07.013] [Reference Citation Analysis]
101 Valenti L, Pelusi S. Redefining fatty liver disease classification in 2020. Liver Int 2020;40:1016-7. [DOI: 10.1111/liv.14430] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 20.0] [Reference Citation Analysis]
102 Harrison SA, Gawrieh S, Roberts K, Lisanti CJ, Schwope RB, Cebe KM, Paradis V, Bedossa P, Aldridge Whitehead JM, Labourdette A, Miette V, Neubauer S, Fournier C, Paredes AH, Alkhouri N. Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort. J Hepatol 2021;75:284-91. [PMID: 33746083 DOI: 10.1016/j.jhep.2021.02.034] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
103 DiStefano JK. Fructose-mediated effects on gene expression and epigenetic mechanisms associated with NAFLD pathogenesis. Cell Mol Life Sci 2020;77:2079-90. [PMID: 31760464 DOI: 10.1007/s00018-019-03390-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 15.0] [Reference Citation Analysis]
104 Lefebvre P, Staels B. Hepatic sexual dimorphism - implications for non-alcoholic fatty liver disease. Nat Rev Endocrinol 2021;17:662-70. [PMID: 34417588 DOI: 10.1038/s41574-021-00538-6] [Reference Citation Analysis]
105 Poynard T, Paradis V, Mullaert J, Deckmyn O, Gault N, Marcault E, Manchon P, Si Mohammed N, Parfait B, Ibberson M, Gautier JF, Boitard C, Czernichow S, Larger E, Drane F, Castille JM, Peta V, Brzustowski A, Terris B, Vallet-Pichard A, Roulot D, Laouénan C, Bedossa P, Castera L, Pol S, Valla D; Quid-Nash consortium. Prospective external validation of a new non-invasive test for the diagnosis of non-alcoholic steatohepatitis in patients with type 2 diabetes. Aliment Pharmacol Ther 2021;54:952-66. [PMID: 34398492 DOI: 10.1111/apt.16543] [Reference Citation Analysis]
106 Waghorn PA, Ferreira DS, Erstad DJ, Rotile NJ, Masia R, Jones CM, Tu C, Sojoodi M, Chen YI, Schlerman F, Wellen J, Martinez RVP, Tanabe KK, Fuchs BC, Caravan P. Quantitative, noninvasive MRI characterization of disease progression in a mouse model of non-alcoholic steatohepatitis. Sci Rep 2021;11:6105. [PMID: 33731798 DOI: 10.1038/s41598-021-85679-4] [Reference Citation Analysis]
107 Honda Y, Imajo K, Kobayashi T, Kessoku T, Ogawa Y, Tomeno W, Yoneda M, Kobayashi N, Saito S, Nakajima A. Autotaxin is a valuable biomarker for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. Hepatol Res 2019;49:1136-46. [PMID: 31144415 DOI: 10.1111/hepr.13382] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
108 Stiglund N, Strand K, Cornillet M, Stål P, Thorell A, Zimmer CL, Näslund E, Karlgren S, Nilsson H, Mellgren G, Fernø J, Hagström H, Björkström NK. Retained NK Cell Phenotype and Functionality in Non-alcoholic Fatty Liver Disease. Front Immunol 2019;10:1255. [PMID: 31214196 DOI: 10.3389/fimmu.2019.01255] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 10.5] [Reference Citation Analysis]
109 Feng G, Zheng KI, Li YY, Rios RS, Zhu PW, Pan XY, Li G, Ma HL, Tang LJ, Byrne CD, Targher G, He N, Mi M, Chen YP, Zheng MH. Machine learning algorithm outperforms fibrosis markers in predicting significant fibrosis in biopsy-confirmed NAFLD. J Hepatobiliary Pancreat Sci 2021;28:593-603. [PMID: 33908180 DOI: 10.1002/jhbp.972] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
110 Sanai FM, Abaalkhail F, Hasan F, Farooqi MH, Nahdi NA, Younossi ZM. Management of nonalcoholic fatty liver disease in the Middle East. World J Gastroenterol 2020; 26(25): 3528-3541 [PMID: 32742124 DOI: 10.3748/wjg.v26.i25.3528] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
111 Caussy C. Should We Screen High-Risk Populations for NAFLD? Curr Hepatology Rep 2019;18:433-43. [DOI: 10.1007/s11901-019-00497-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
112 Couzigou P. [Nutritional steatosis a drug target, or more especially anchor point for a holistic approach?]. Presse Med 2019;48:1016-8. [PMID: 31787171 DOI: 10.1016/j.lpm.2019.10.025] [Reference Citation Analysis]
113 Rowe IA, Parker R. The diagnosis of nonalcoholic fatty liver disease should carry important prognostic information. Nat Rev Gastroenterol Hepatol 2019;16:449-50. [PMID: 31197261 DOI: 10.1038/s41575-019-0168-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
114 Ulmasov B, Noritake H, Carmichael P, Oshima K, Griggs DW, Neuschwander-Tetri BA. An Inhibitor of Arginine-Glycine-Aspartate-Binding Integrins Reverses Fibrosis in a Mouse Model of Nonalcoholic Steatohepatitis. Hepatol Commun 2019;3:246-61. [PMID: 30766962 DOI: 10.1002/hep4.1298] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
115 Arai T, Atsukawa M, Tsubota A, Kawano T, Koeda M, Yoshida Y, Tanabe T, Okubo T, Hayama K, Iwashita A, Itokawa N, Kondo C, Kaneko K, Kawamoto C, Hatori T, Emoto N, Iio E, Tanaka Y, Iwakiri K. Factors influencing subclinical atherosclerosis in patients with biopsy-proven nonalcoholic fatty liver disease. PLoS One 2019;14:e0224184. [PMID: 31721770 DOI: 10.1371/journal.pone.0224184] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
116 Mikolasevic I, Filipec-Kanizaj T, Mijic M, Jakopcic I, Milic S, Hrstic I, Sobocan N, Stimac D, Burra P. Nonalcoholic fatty liver disease and liver transplantation - Where do we stand? World J Gastroenterol 2018; 24(14): 1491-1506 [PMID: 29662288 DOI: 10.3748/wjg.v24.i14.1491] [Cited by in CrossRef: 50] [Cited by in F6Publishing: 43] [Article Influence: 16.7] [Reference Citation Analysis]
117 Rowe IA, Wong VW, Loomba R. Treatment Candidacy for Pharmacologic Therapies for NASH. Clinical Gastroenterology and Hepatology 2021. [DOI: 10.1016/j.cgh.2021.03.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
118 Ballestri S, Mantovani A, Baldelli E, Lugari S, Maurantonio M, Nascimbeni F, Marrazzo A, Romagnoli D, Targher G, Lonardo A. Liver Fibrosis Biomarkers Accurately Exclude Advanced Fibrosis and Are Associated with Higher Cardiovascular Risk Scores in Patients with NAFLD or Viral Chronic Liver Disease. Diagnostics (Basel) 2021;11:98. [PMID: 33435415 DOI: 10.3390/diagnostics11010098] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 13.0] [Reference Citation Analysis]
119 Roskilly A, Hicks A, Taylor EJ, Jones R, Parker R, Rowe IA. Fibrosis progression rate in a systematic review of placebo-treated nonalcoholic steatohepatitis. Liver Int 2021;41:982-95. [PMID: 33283415 DOI: 10.1111/liv.14749] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
120 Niriella MA, Ediriweera DS, Kasturiratne A, De Silva ST, Dassanayaka AS, De Silva AP, Kato N, Pathmeswaran A, Wickramasinghe AR, de Silva HJ. Outcomes of NAFLD and MAFLD: Results from a community-based, prospective cohort study. PLoS One 2021;16:e0245762. [PMID: 33534815 DOI: 10.1371/journal.pone.0245762] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 9.0] [Reference Citation Analysis]
121 Zhou YJ, Ye FZ, Li YY, Pan XY, Chen YX, Wu XX, Xiong JJ, Liu WY, Xu SH, Chen YP, Zheng MH. Individualized risk prediction of significant fibrosis in non-alcoholic fatty liver disease using a novel nomogram. United European Gastroenterol J 2019;7:1124-34. [PMID: 31662869 DOI: 10.1177/2050640619868352] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
122 Golabi P, Rhea L, Henry L, Younossi ZM. Hepatocellular carcinoma and non-alcoholic fatty liver disease. Hepatol Int. 2019;13:688-694. [PMID: 31701393 DOI: 10.1007/s12072-019-09995-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 6.5] [Reference Citation Analysis]
123 Hagström H, Kechagias S, Ekstedt M. Risk for hepatic and extra-hepatic outcomes in nonalcoholic fatty liver disease. J Intern Med 2021. [PMID: 34118091 DOI: 10.1111/joim.13343] [Reference Citation Analysis]
124 Dhar D, Baglieri J, Kisseleva T, Brenner DA. Mechanisms of liver fibrosis and its role in liver cancer. Exp Biol Med (Maywood) 2020;245:96-108. [PMID: 31924111 DOI: 10.1177/1535370219898141] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 15.0] [Reference Citation Analysis]
125 Boursier J, Guillaume M, Bouzbib C, Lannes A, Pais R, Smatti S, Cariou B, Bureau C, Ganne-Carrié N, Bourlière M, de Lédinghen V. NON-INVASIVE DIAGNOSIS AND FOLLOW-UP OF NON-ALCOHOLIC FATTY LIVER DISEASE. Clin Res Hepatol Gastroenterol 2021;:101769. [PMID: 34332133 DOI: 10.1016/j.clinre.2021.101769] [Reference Citation Analysis]
126 Kozumi K, Kodama T, Murai H, Sakane S, Govaere O, Cockell S, Motooka D, Kakita N, Yamada Y, Kondo Y, Tahata Y, Yamada R, Hikita H, Sakamori R, Kamada Y, Daly AK, Anstee QM, Tatsumi T, Morii E, Takehara T. Transcriptomics Identify Thrombospondin-2 as a Biomarker for NASH and Advanced Liver Fibrosis. Hepatology 2021. [PMID: 34105780 DOI: 10.1002/hep.31995] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
127 Jarvis H, Craig D, Barker R, Spiers G, Stow D, Anstee QM, Hanratty B. Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of population-based observational studies. PLoS Med. 2020;17:e1003100. [PMID: 32353039 DOI: 10.1371/journal.pmed.1003100] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 26.0] [Reference Citation Analysis]
128 Caballeria L, Augustin S, Broquetas T, Morillas RM, Vergara M, Virolés S, Hernández MR, Serra I, Goday A, Vila L, Siso-Almirall A, Solans R, Fernández-Real JM, Carrión JA, Graupera I, Ginès P. Recommendations for the detection, diagnosis and follow-up of patients with non-alcoholic fatty liver disease in primary and hospital care. Med Clin (Barc) 2019;153:169-77. [PMID: 31178295 DOI: 10.1016/j.medcli.2019.01.030] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
129 Sanyal A, Charles ED, Neuschwander-tetri BA, Loomba R, Harrison SA, Abdelmalek MF, Lawitz EJ, Halegoua-demarzio D, Kundu S, Noviello S, Luo Y, Christian R. Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial. The Lancet 2018;392:2705-17. [DOI: 10.1016/s0140-6736(18)31785-9] [Cited by in Crossref: 156] [Cited by in F6Publishing: 90] [Article Influence: 52.0] [Reference Citation Analysis]
130 Lee DH. Noninvasive Evaluation of Nonalcoholic Fatty Liver Disease. Endocrinol Metab (Seoul) 2020;35:243-59. [PMID: 32615709 DOI: 10.3803/EnM.2020.35.2.243] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 5.0] [Reference Citation Analysis]
131 Cotter TG, Rinella M. Nonalcoholic Fatty Liver Disease 2020: The State of the Disease. Gastroenterology 2020;158:1851-64. [PMID: 32061595 DOI: 10.1053/j.gastro.2020.01.052] [Cited by in Crossref: 120] [Cited by in F6Publishing: 138] [Article Influence: 120.0] [Reference Citation Analysis]
132 Ye Q, Zou B, Yeo YH, Li J, Huang DQ, Wu Y, Yang H, Liu C, Kam LY, Tan XXE, Chien N, Trinh S, Henry L, Stave CD, Hosaka T, Cheung RC, Nguyen MH. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5:739-752. [PMID: 32413340 DOI: 10.1016/s2468-1253(20)30077-7] [Cited by in Crossref: 85] [Cited by in F6Publishing: 42] [Article Influence: 85.0] [Reference Citation Analysis]
133 Ogawa Y, Honda Y, Kessoku T, Tomeno W, Imajo K, Yoneda M, Kawanaka M, Kirikoshi H, Ono M, Taguri M, Saito S, Yamanaka T, Wada K, Nakajima A. Wisteria floribunda agglutinin-positive Mac-2-binding protein and type 4 collagen 7S: useful markers for the diagnosis of significant fibrosis in patients with non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2018;33:1795-1803. [PMID: 29633352 DOI: 10.1111/jgh.14156] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 7.3] [Reference Citation Analysis]
134 Goldman O, Ben-Assuli O, Rogowski O, Zeltser D, Shapira I, Berliner S, Zelber-Sagi S, Shenhar-Tsarfaty S. Non-alcoholic Fatty Liver and Liver Fibrosis Predictive Analytics: Risk Prediction and Machine Learning Techniques for Improved Preventive Medicine. J Med Syst 2021;45:22. [PMID: 33426569 DOI: 10.1007/s10916-020-01693-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
135 Liu CH, Ampuero J, Pavlides M, Wong VW, Fan JG, Bai L, Li H, Wu DB, Zhou LY, Du LY, Yang TK, Jiang W, Shi Y, Gil-Gómez A, Zhang WT, Liang JX, Romero-Gómez M, Tang H. Simple non-invasive scoring systems and histological scores in predicting mortality in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis. J Gastroenterol Hepatol 2021;36:1754-68. [PMID: 33569851 DOI: 10.1111/jgh.15431] [Reference Citation Analysis]
136 Turchinovich A, Baranova A, Drapkina O, Tonevitsky A. Cell-Free Circulating Nucleic Acids as Early Biomarkers for NAFLD and NAFLD-Associated Disorders. Front Physiol 2018;9:1256. [PMID: 30294278 DOI: 10.3389/fphys.2018.01256] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
137 Swain MG, Ramji A, Patel K, Sebastiani G, Shaheen AA, Tam E, Marotta P, Elkhashab M, Bajaj HS, Estes C, Razavi H. Burden of nonalcoholic fatty liver disease in Canada, 2019-2030: a modelling study. CMAJ Open 2020;8:E429-36. [PMID: 32518095 DOI: 10.9778/cmajo.20190212] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
138 Hagström H, Elfwén O, Hultcrantz R, Stål P. Steatohepatitis Is Not Associated with an Increased Risk for Fibrosis Progression in Nonalcoholic Fatty Liver Disease. Gastroenterol Res Pract 2018;2018:1942648. [PMID: 30057598 DOI: 10.1155/2018/1942648] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
139 Imajo K, Honda Y, Yoneda M, Saito S, Nakajima A. Magnetic resonance imaging for the assessment of pathological hepatic findings in nonalcoholic fatty liver disease. J Med Ultrason (2001) 2020;47:535-48. [PMID: 33108553 DOI: 10.1007/s10396-020-01059-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
140 Guillaume M, Moal V, Delabaudiere C, Zuberbuhler F, Robic MA, Lannes A, Metivier S, Oberti F, Gourdy P, Fouchard-Hubert I, Selves J, Michalak S, Peron JM, Cales P, Bureau C, Boursier J. Direct comparison of the specialised blood fibrosis tests FibroMeterV2G and Enhanced Liver Fibrosis score in patients with non-alcoholic fatty liver disease from tertiary care centres. Aliment Pharmacol Ther 2019;50:1214-22. [PMID: 31617224 DOI: 10.1111/apt.15529] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
141 Patikorn C, Veettil SK, Phisalprapa P, Pham T, Kowdley KV, Chaiyakunapruk N. Horizon scanning of therapeutic modalities for nonalcoholic steatohepatitis. Ann Hepatol 2021;24:100315. [PMID: 33515800 DOI: 10.1016/j.aohep.2021.100315] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
142 Levy JJ, Azizgolshani N, Andersen MJ Jr, Suriawinata A, Liu X, Lisovsky M, Ren B, Bobak CA, Christensen BC, Vaickus LJ. A large-scale internal validation study of unsupervised virtual trichrome staining technologies on nonalcoholic steatohepatitis liver biopsies. Mod Pathol 2021;34:808-22. [PMID: 33299110 DOI: 10.1038/s41379-020-00718-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
143 Bisaccia G, Ricci F, Mantini C, Tana C, Romani GL, Schiavone C, Gallina S. Nonalcoholic fatty liver disease and cardiovascular disease phenotypes. SAGE Open Med 2020;8:2050312120933804. [PMID: 32612827 DOI: 10.1177/2050312120933804] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
144 Serra-burriel M, Graupera I, Torán P, Thiele M, Roulot D, Wai-sun Wong V, Neil Guha I, Fabrellas N, Arslanow A, Expósito C, Hernández R, Lai-hung Wong G, Harman D, Darwish Murad S, Krag A, Pera G, Angeli P, Galle P, Aithal GP, Caballeria L, Castera L, Ginès P, Lammert F. Transient elastography for screening of liver fibrosis: Cost-effectiveness analysis from six prospective cohorts in Europe and Asia. Journal of Hepatology 2019;71:1141-51. [DOI: 10.1016/j.jhep.2019.08.019] [Cited by in Crossref: 41] [Cited by in F6Publishing: 31] [Article Influence: 20.5] [Reference Citation Analysis]
145 Allen J, Zhang J, Quickel MD, Kennett M, Patterson AD, Hankey-Giblin PA. Ron Receptor Signaling Ameliorates Hepatic Fibrosis in a Diet-Induced Nonalcoholic Steatohepatitis Mouse Model. J Proteome Res 2018;17:3268-80. [PMID: 30091925 DOI: 10.1021/acs.jproteome.8b00379] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
146 Davison BA, Harrison SA, Cotter G, Alkhouri N, Sanyal A, Edwards C, Colca JR, Iwashita J, Koch GG, Dittrich HC. Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials. J Hepatol. 2020;73:1322-1332. [PMID: 32610115 DOI: 10.1016/j.jhep.2020.06.025] [Cited by in Crossref: 46] [Cited by in F6Publishing: 49] [Article Influence: 46.0] [Reference Citation Analysis]
147 Cherla DV, Rodriguez NA, Vangoitsenhoven R, Singh T, Mehta N, McCullough AJ, Brethauer SA, Schauer PR, Aminian A. Impact of sleeve gastrectomy and Roux-en-Y gastric bypass on biopsy-proven non-alcoholic fatty liver disease. Surg Endosc 2020;34:2266-72. [PMID: 31359195 DOI: 10.1007/s00464-019-07017-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
148 Li YK, Li YM, Li Y, Wei YR, Zhang J, Li B, You ZR, Chen Y, Huang BY, Miao Q, Wang QX, Peng YS, Gershwin ME, Tang RQ, Bian ZL, Ma X. CTHRC1 expression in primary biliary cholangitis. J Dig Dis 2019;20:371-6. [PMID: 31102333 DOI: 10.1111/1751-2980.12791] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
149 Vuppalanchi R, Noureddin M, Alkhouri N, Sanyal AJ. Therapeutic pipeline in nonalcoholic steatohepatitis. Nat Rev Gastroenterol Hepatol 2021;18:373-92. [PMID: 33568794 DOI: 10.1038/s41575-020-00408-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 14.0] [Reference Citation Analysis]
150 Taylor RS, Taylor RJ, Bayliss S, Hagström H, Nasr P, Schattenberg JM, Ishigami M, Toyoda H, Wai-Sun Wong V, Peleg N, Shlomai A, Sebastiani G, Seko Y, Bhala N, Younossi ZM, Anstee QM, McPherson S, Newsome PN. Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Gastroenterology 2020;158:1611-1625.e12. [PMID: 32027911 DOI: 10.1053/j.gastro.2020.01.043] [Cited by in Crossref: 150] [Cited by in F6Publishing: 143] [Article Influence: 150.0] [Reference Citation Analysis]
151 Do A, Ilagan-Ying YC, Mehal WZ, Lim JK. Drug development of nonalcoholic fatty liver disease: challenges in research, regulatory pathways, and study endpoints. Expert Opin Drug Discov 2021;16:125-34. [PMID: 33086894 DOI: 10.1080/17460441.2020.1811674] [Reference Citation Analysis]
152 Hagström H, Nasr P, Ekstedt M, Stål P, Hultcrantz R, Kechagias S. Accuracy of Noninvasive Scoring Systems in Assessing Risk of Death and Liver-Related Endpoints in Patients With Nonalcoholic Fatty Liver Disease. Clinical Gastroenterology and Hepatology 2019;17:1148-1156.e4. [DOI: 10.1016/j.cgh.2018.11.030] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 14.0] [Reference Citation Analysis]
153 Ligat G, Schuster C, Baumert TF. Hepatitis B Virus Core Variants, Liver Fibrosis, and Hepatocellular Carcinoma. Hepatology 2019;69:5-8. [PMID: 30137676 DOI: 10.1002/hep.30231] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 8.0] [Reference Citation Analysis]
154 De Chiara F, Ferret-Miñana A, Ramón-Azcón J. The Synergy between Organ-on-a-Chip and Artificial Intelligence for the Study of NAFLD: From Basic Science to Clinical Research. Biomedicines 2021;9:248. [PMID: 33801289 DOI: 10.3390/biomedicines9030248] [Reference Citation Analysis]
155 Baffy G. Origins of Portal Hypertension in Nonalcoholic Fatty Liver Disease. Dig Dis Sci 2018;63:563-76. [DOI: 10.1007/s10620-017-4903-5] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
156 Wijarnpreecha K, Aby ES, Panjawatanan P, Lapumnuaypol K, Cheungpasitporn W, Lukens FJ, Harnois DM, Ungprasert P. Modest alcohol consumption and risk of advanced liver fibrosis in nonalcoholic fatty liver disease: a systematic review and meta-analysis. Ann Gastroenterol 2021;34:568-74. [PMID: 34276197 DOI: 10.20524/aog.2021.0612] [Reference Citation Analysis]
157 Forlano R, Mullish BH, Giannakeas N, Maurice JB, Angkathunyakul N, Lloyd J, Tzallas AT, Tsipouras M, Yee M, Thursz MR, Goldin RD, Manousou P. High-Throughput, Machine Learning-Based Quantification of Steatosis, Inflammation, Ballooning, and Fibrosis in Biopsies From Patients With Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol 2020; 18: 2081-2090. e9. [PMID: 31887451 DOI: 10.1016/j.cgh.2019.12.025] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 8.5] [Reference Citation Analysis]
158 Arrese M, Barrera F, Triantafilo N, Arab JP. Concurrent nonalcoholic fatty liver disease and type 2 diabetes: diagnostic and therapeutic considerations. Expert Review of Gastroenterology & Hepatology 2019;13:849-66. [DOI: 10.1080/17474124.2019.1649981] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 9.0] [Reference Citation Analysis]
159 Ogawa K, Kobayashi T, Furukawa JI, Hanamatsu H, Nakamura A, Suzuki K, Kawagishi N, Ohara M, Umemura M, Nakai M, Sho T, Suda G, Morikawa K, Baba M, Furuya K, Terashita K, Kobayashi T, Onodera M, Horimoto T, Shinada K, Tsunematsu S, Tsunematsu I, Meguro T, Mitsuhashi T, Hato M, Higashino K, Shinohara Y, Sakamoto N. Tri-antennary tri-sialylated mono-fucosylated glycan of alpha-1 antitrypsin as a non-invasive biomarker for non-alcoholic steatohepatitis: a novel glycobiomarker for non-alcoholic steatohepatitis. Sci Rep 2020;10:321. [PMID: 31941930 DOI: 10.1038/s41598-019-56947-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
160 Hagström H, Talbäck M, Andreasson A, Walldius G, Hammar N. Repeated FIB-4 measurements can help identify individuals at risk of severe liver disease. J Hepatol 2020;73:1023-9. [PMID: 32621944 DOI: 10.1016/j.jhep.2020.06.007] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 13.0] [Reference Citation Analysis]
161 Pai RK, Kleiner DE, Hart J, Adeyi OA, Clouston AD, Behling CA, Jain D, Kakar S, Brahmania M, Burgart L, Batts KP, Valasek MA, Torbenson MS, Guindi M, Wang HL, Ajmera V, Adams LA, Parker CE, Feagan BG, Loomba R, Jairath V. Standardising the interpretation of liver biopsies in non-alcoholic fatty liver disease clinical trials. Aliment Pharmacol Ther 2019;50:1100-11. [PMID: 31583739 DOI: 10.1111/apt.15503] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
162 Zheng J, Chen S, Cai Y, Lin S, Ke S, Liu L. Insufficient nocturnal sleep was associated with a higher risk of fibrosis in patients with diabetes with metabolic associated fatty liver disease. Ther Adv Endocrinol Metab 2020;11:2042018820947550. [PMID: 32973993 DOI: 10.1177/2042018820947550] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
163 Kang MK, Baek JH, Kweon YO, Tak WY, Jang SY, Lee YR, Hur K, Kim G, Lee HW, Han MH, Choi JH, Park SY, Park JG. Association of Skeletal Muscle and Adipose Tissue Distribution with Histologic Severity of Non-Alcoholic Fatty Liver. Diagnostics (Basel) 2021;11:1061. [PMID: 34207587 DOI: 10.3390/diagnostics11061061] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
164 Simon TG, Roelstraete B, Sharma R, Khalili H, Hagström H, Ludvigsson JF. Cancer Risk in Patients With Biopsy-Confirmed Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study. Hepatology 2021. [PMID: 33811766 DOI: 10.1002/hep.31845] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
165 Daniels SJ, Leeming DJ, Eslam M, Hashem AM, Nielsen MJ, Krag A, Karsdal MA, Grove JI, Guha IN, Kawaguchi T, Torimura T, McLeod D, Akiba J, Kaye P, de Boer B, Aithal GP, Adams LA, George J. ADAPT: An algorithm incorporating PRO-C3 accurately identifies patients with NAFLD and advanced fibrosis. Hepatology. 2018;. [PMID: 30014517 DOI: 10.1002/hep.30163] [Cited by in Crossref: 72] [Cited by in F6Publishing: 69] [Article Influence: 72.0] [Reference Citation Analysis]
166 Tamargo JA, Sherman KE, Campa A, Martinez SS, Li T, Hernandez J, Teeman C, Mandler RN, Chen J, Ehman RL, Baum MK. Food insecurity is associated with magnetic resonance-determined nonalcoholic fatty liver and liver fibrosis in low-income, middle-aged adults with and without HIV. Am J Clin Nutr 2021;113:593-601. [PMID: 33515016 DOI: 10.1093/ajcn/nqaa362] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
167 Bernal-Reyes R, Castro-Narro G, Malé-Velázquez R, Carmona-Sánchez R, González-Huezo MS, García-Juárez I, Chávez-Tapia N, Aguilar-Salinas C, Aiza-Haddad I, Ballesteros-Amozurrutia MA, Bosques-Padilla F, Castillo-Barradas M, Chávez-Barrera JA, Cisneros-Garza L, Flores-Calderón J, García-Compeán D, Gutiérrez-Grobe Y, Higuera de la Tijera MF, Kershenobich-Stalnikowitz D, Ladrón de Guevara-Cetina L, Lizardi-Cervera J, López-Cossio JA, Martínez-Vázquez S, Márquez-Guillén E, Méndez-Sánchez N, Moreno-Alcantar R, Poo-Ramírez JL, Ramos-Martínez P, Rodríguez-Hernández H, Sánchez-Ávila JF, Stoopen-Rometti M, Torre-Delgadillo A, Torres-Villalobos G, Trejo-Estrada R, Uribe-Esquivel M, Velarde-Ruiz Velasco JA. The Mexican consensus on nonalcoholic fatty liver disease.Rev Gastroenterol Mex (Engl Ed). 2019;84:69-99. [PMID: 30711302 DOI: 10.1016/j.rgmx.2018.11.007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
168 Tamaki N, Munaganuru N, Jung J, Yonan AQ, Loomba RR, Bettencourt R, Ajmera V, Valasek MA, Behling C, Sirlin CB, Loomba R. Clinical utility of 30% relative decline in MRI-PDFF in predicting fibrosis regression in non-alcoholic fatty liver disease. Gut 2021:gutjnl-2021-324264. [PMID: 33883248 DOI: 10.1136/gutjnl-2021-324264] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
169 Ogawa M, Tsuchiya A, Watanabe T, Setsu T, Kimura N, Matsuda M, Hoshiyama Y, Saito H, Kanazawa T, Shiotani M, Sato T, Yagi T, Igarashi K, Yoshimura N, Takamura M, Aoyama H, Terai S. Screening and follow-up of chronic liver diseases with understanding their etiology in clinics and hospitals. JGH Open 2020;4:827-37. [PMID: 33102751 DOI: 10.1002/jgh3.12406] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
170 Ferrusquía-acosta J, Bassegoda O, Turco L, Reverter E, Pellone M, Bianchini M, Pérez-campuzano V, Ripoll E, García-criado Á, Graupera I, García-pagán JC, Schepis F, Senzolo M, Hernández-gea V. Agreement between wedged hepatic venous pressure and portal pressure in non-alcoholic steatohepatitis-related cirrhosis. Journal of Hepatology 2021;74:811-8. [DOI: 10.1016/j.jhep.2020.10.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
171 Saoi M, Sasaki K, Sagawa H, Abe K, Kogiso T, Tokushige K, Hashimoto E, Ohashi Y, Britz-McKibbin P. High Throughput Screening of Serum γ-Glutamyl Dipeptides for Risk Assessment of Nonalcoholic Steatohepatitis with Impaired Glutathione Salvage Pathway. J Proteome Res 2020;19:2689-99. [PMID: 31483669 DOI: 10.1021/acs.jproteome.9b00405] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
172 Yang F, Jia X, Lei P, He Y, Xiang Y, Jiao J, Zhou S, Qian W, Duan Q. Quantification of hepatic steatosis in histologic images by deep learning method. J Xray Sci Technol 2019;27:1033-45. [PMID: 31744039 DOI: 10.3233/XST-190570] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
173 Balakrishnan M, Patel P, Dunn-valadez S, Dao C, Khan V, Ali H, El-serag L, Hernaez R, Sisson A, Thrift AP, Liu Y, El-serag HB, Kanwal F. Women Have a Lower Risk of Nonalcoholic Fatty Liver Disease but a Higher Risk of Progression vs Men: A Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology 2021;19:61-71.e15. [DOI: 10.1016/j.cgh.2020.04.067] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 24.0] [Reference Citation Analysis]
174 Okanoue T, Shima T, Mitsumoto Y, Umemura A, Yamaguchi K, Itoh Y, Yoneda M, Nakajima A, Mizukoshi E, Kaneko S, Harada K. Artificial intelligence/neural network system for the screening of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatol Res 2021;51:554-69. [PMID: 33594747 DOI: 10.1111/hepr.13628] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
175 Han MAT. Noninvasive Tests (NITs) for Hepatic Fibrosis in Fatty Liver Syndrome. Life (Basel) 2020;10:E198. [PMID: 32933184 DOI: 10.3390/life10090198] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
176 Vaz J, Eriksson B, Strömberg U, Buchebner D, Midlöv P. Incidence, aetiology and related comorbidities of cirrhosis: a Swedish population-based cohort study. BMC Gastroenterol 2020;20:84. [PMID: 32245414 DOI: 10.1186/s12876-020-01239-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
177 Paternostro R, Sieghart W, Trauner M, Pinter M. Cancer and hepatic steatosis. ESMO Open 2021;6:100185. [PMID: 34139486 DOI: 10.1016/j.esmoop.2021.100185] [Reference Citation Analysis]
178 Hernandez Roman J, Siddiqui MS. The role of noninvasive biomarkers in diagnosis and risk stratification in nonalcoholic fatty liver disease. Endocrinol Diabetes Metab 2020;3:e00127. [PMID: 33102796 DOI: 10.1002/edm2.127] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
179 Kleiner DE, Brunt EM, Wilson LA, Behling C, Guy C, Contos M, Cummings O, Yeh M, Gill R, Chalasani N, Neuschwander-Tetri BA, Diehl AM, Dasarathy S, Terrault N, Kowdley K, Loomba R, Belt P, Tonascia J, Lavine JE, Sanyal AJ;  Nonalcoholic Steatohepatitis Clinical Research Network. Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver Disease. JAMA Netw Open. 2019;2:e1912565. [PMID: 31584681 DOI: 10.1001/jamanetworkopen.2019.12565] [Cited by in Crossref: 80] [Cited by in F6Publishing: 77] [Article Influence: 40.0] [Reference Citation Analysis]
180 Nasr P, Iredahl F, Dahlström N, Rådholm K, Henriksson P, Cedersund G, Dahlqvist Leinhard O, Ebbers T, Alfredsson J, Carlhäll CJ, Lundberg P, Kechagias S, Ekstedt M. Evaluating the prevalence and severity of NAFLD in primary care: the EPSONIP study protocol. BMC Gastroenterol 2021;21:180. [PMID: 33879084 DOI: 10.1186/s12876-021-01763-z] [Reference Citation Analysis]
181 Parthasarathy G, Revelo X, Malhi H. Pathogenesis of Nonalcoholic Steatohepatitis: An Overview. Hepatol Commun 2020;4:478-92. [PMID: 32258944 DOI: 10.1002/hep4.1479] [Cited by in Crossref: 50] [Cited by in F6Publishing: 49] [Article Influence: 50.0] [Reference Citation Analysis]
182 Aithal GP. Commentary: non-alcoholic steatohepatitis-finding and minding the fire behind the smoke. Aliment Pharmacol Ther 2020;51:209-11. [PMID: 31850574 DOI: 10.1111/apt.15565] [Reference Citation Analysis]
183 De Chiara F, Ureta Checcllo C, Ramón Azcón J. High Protein Diet and Metabolic Plasticity in Non-Alcoholic Fatty Liver Disease: Myths and Truths. Nutrients 2019;11:E2985. [PMID: 31817648 DOI: 10.3390/nu11122985] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
184 Sharpton SR, Tamaki N, Bettencourt R, Madamba E, Jung J, Liu A, Behling C, Valasek MA, Loomba R. Diagnostic accuracy of two-dimensional shear wave elastography and transient elastography in nonalcoholic fatty liver disease. Therap Adv Gastroenterol 2021;14:17562848211050436. [PMID: 34646360 DOI: 10.1177/17562848211050436] [Reference Citation Analysis]
185 Cernea S, Raz I. NAFLD in type 2 diabetes mellitus: Still many challenging questions. Diabetes Metab Res Rev 2021;37. [DOI: 10.1002/dmrr.3386] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
186 Ali AH, Petroski GF, Diaz-Arias AA, Al Juboori A, Wheeler AA, Ganga RR, Pitt JB, Spencer NM, Hammoud GM, Rector RS, Parks EJ, Ibdah JA. A Model Incorporating Serum Alkaline Phosphatase for Prediction of Liver Fibrosis in Adults with Obesity and Nonalcoholic Fatty Liver Disease. J Clin Med 2021;10:3311. [PMID: 34362095 DOI: 10.3390/jcm10153311] [Reference Citation Analysis]
187 Francque SM, Marchesini G, Kautz A, Walmsley M, Dorner R, Lazarus JV, Zelber-Sagi S, Hallsworth K, Busetto L, Frühbeck G, Dicker D, Woodward E, Korenjak M, Willemse J, Koek GH, Vinker S, Ungan M, Mendive JM, Lionis C. Non-alcoholic fatty liver disease: A patient guideline. JHEP Rep 2021;3:100322. [PMID: 34693236 DOI: 10.1016/j.jhepr.2021.100322] [Reference Citation Analysis]
188 Kechagias S, Nasr P, Blomdahl J, Ekstedt M. Established and emerging factors affecting the progression of nonalcoholic fatty liver disease. Metabolism 2020;111S:154183. [PMID: 32061907 DOI: 10.1016/j.metabol.2020.154183] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 14.0] [Reference Citation Analysis]
189 Liu XJ, Xie L, Du K, Liu C, Zhang NP, Gu CJ, Wang Y, Abdelmalek MF, Dong WY, Liu XP, Niu C, Yang C, Diehl AM, Wu J. Succinate-GPR-91 receptor signalling is responsible for nonalcoholic steatohepatitis-associated fibrosis: Effects of DHA supplementation. Liver Int. 2020;40:830-843. [PMID: 31903720 DOI: 10.1111/liv.14370] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
190 Kim D, Kim W, Adejumo AC, Cholankeril G, Tighe SP, Wong RJ, Gonzalez SA, Harrison SA, Younossi ZM, Ahmed A. Race/ethnicity-based temporal changes in prevalence of NAFLD-related advanced fibrosis in the United States, 2005-2016. Hepatol Int 2019;13:205-13. [PMID: 30694445 DOI: 10.1007/s12072-018-09926-z] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 13.0] [Reference Citation Analysis]
191 Yang X, Chang X, Wu S, Sun X, Zhu X, Wang L, Xu Y, Yao X, Rao S, Hu X, Xia M, Bian H, Yan H, Gao X. Performance of liver stiffness measurements obtained with FibroScan is affected by glucose metabolism in patients with nonalcoholic fatty liver disease. Lipids Health Dis 2021;20:27. [PMID: 33757528 DOI: 10.1186/s12944-021-01453-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
192 Geier A, Tiniakos D, Denk H, Trauner M. From the origin of NASH to the future of metabolic fatty liver disease. Gut 2021:gutjnl-2020-323202. [PMID: 33632710 DOI: 10.1136/gutjnl-2020-323202] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
193 Armandi A, Schattenberg JM. Beyond the Paradigm of Weight Loss in Non-Alcoholic Fatty Liver Disease: From Pathophysiology to Novel Dietary Approaches. Nutrients 2021;13:1977. [PMID: 34201382 DOI: 10.3390/nu13061977] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
194 Thiagarajan P, Chalmers J, Guha IN, James MW. Detecting chronic liver disease: are liver function tests the solution? Br J Hosp Med (Lond) 2020;81:1-8. [PMID: 32097065 DOI: 10.12968/hmed.2019.0308] [Reference Citation Analysis]
195 Iruzubieta P, Arias-Loste MT, Fortea JI, Cuadrado A, Rivas-Rivas C, Rodriguez-Duque JC, García-Ibarbia C, Hernández JL, Crespo J. National digestive disease specialists survey on cardiovascular risk management in non-alcoholic fatty liver disease in spanish hospitals. Liver Int 2021;41:1243-53. [PMID: 33527637 DOI: 10.1111/liv.14807] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
196 Gitto S, Marra F, De Maria N, Bihl F, Villa E, Andreone P, Burra P. Nonalcoholic steatohepatitis before and after liver transplant: keeping up with the times. Expert Review of Gastroenterology & Hepatology 2018;13:173-8. [DOI: 10.1080/17474124.2019.1551132] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
197 Shah S, Dhami-Shah H, Kamble S, Shukla A. FIB-4 cut-off of 1.3 may be inappropriate in a primary care referral pathway for patients with non-alcoholic fatty liver disease. J Hepatol. 2020;73:216-217. [PMID: 32276730 DOI: 10.1016/j.jhep.2019.12.025] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
198 DiStefano JK. NAFLD and NASH in Postmenopausal Women: Implications for Diagnosis and Treatment. Endocrinology 2020;161:bqaa134. [PMID: 32776116 DOI: 10.1210/endocr/bqaa134] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 14.0] [Reference Citation Analysis]
199 Sumida Y, Yoneda M, Ogawa Y, Yoneda M, Okanoue T, Nakajima A. Current and new pharmacotherapy options for non-alcoholic steatohepatitis. Expert Opin Pharmacother 2020;21:953-67. [PMID: 32237916 DOI: 10.1080/14656566.2020.1744564] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
200 Maeso-Díaz R, Boyer-Diaz Z, Lozano JJ, Ortega-Ribera M, Peralta C, Bosch J, Gracia-Sancho J. New Rat Model of Advanced NASH Mimicking Pathophysiological Features and Transcriptomic Signature of The Human Disease. Cells 2019;8:E1062. [PMID: 31510105 DOI: 10.3390/cells8091062] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
201 Zhang X, Wong GL, Wong VW. Application of transient elastography in nonalcoholic fatty liver disease. Clin Mol Hepatol 2020;26:128-41. [PMID: 31696690 DOI: 10.3350/cmh.2019.0001n] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 11.5] [Reference Citation Analysis]
202 Mazzolini G, Sowa JP, Atorrasagasti C, Kücükoglu Ö, Syn WK, Canbay A. Significance of Simple Steatosis: An Update on the Clinical and Molecular Evidence. Cells 2020;9:E2458. [PMID: 33187255 DOI: 10.3390/cells9112458] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
203 Selvaraj EA, Mózes FE, Jayaswal ANA, Zafarmand MH, Vali Y, Lee JA, Levick CK, Young LAJ, Palaniyappan N, Liu CH, Aithal GP, Romero-Gómez M, Brosnan MJ, Tuthill TA, Anstee QM, Neubauer S, Harrison SA, Bossuyt PM, Pavlides M; LITMUS Investigators. Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis. J Hepatol 2021:S0168-8278(21)00309-3. [PMID: 33991635 DOI: 10.1016/j.jhep.2021.04.044] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
204 Puthenpura MM, Patel V, Fam J, Katz L, Tichansky DS, Myers S. The Use of Transient Elastography Technology in the Bariatric Patient: a Review of the Literature. Obes Surg 2020;30:5108-16. [PMID: 32981002 DOI: 10.1007/s11695-020-05002-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
205 Marti-Aguado D, Rodríguez-Ortega A, Alberich-Bayarri A, Marti-Bonmati L. Magnetic Resonance imaging analysis of liver fibrosis and inflammation: overwhelming gray zones restrict clinical use. Abdom Radiol (NY) 2020;45:3557-68. [PMID: 32857259 DOI: 10.1007/s00261-020-02713-1] [Reference Citation Analysis]
206 Chang J, Koseki M, Saga A, Kanno K, Higo T, Okuzaki D, Okada T, Inui H, Tanaka K, Asaji M, Zhu Y, Kamada Y, Ono M, Saibara T, Ichi I, Ohama T, Nishida M, Yamashita S, Sakata Y. Dietary Oxysterol, 7-Ketocholesterol Accelerates Hepatic Lipid Accumulation and Macrophage Infiltration in Obese Mice. Front Endocrinol (Lausanne) 2020;11:614692. [PMID: 33776901 DOI: 10.3389/fendo.2020.614692] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
207 Nyberg LM, Cheetham TC, Patton HM, Yang SJ, Chiang KM, Caparosa SL, Stern JA, Nyberg AH. The Natural History of NAFLD, a Community-Based Study at a Large Health Care Delivery System in the United States. Hepatol Commun 2021;5:83-96. [PMID: 33437903 DOI: 10.1002/hep4.1625] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
208 Schuster-Gaul S, Geisler LJ, McGeough MD, Johnson CD, Zagorska A, Li L, Wree A, Barry V, Mikaelian I, Jih LJ, Papouchado BG, Budas G, Hoffman HM, Feldstein AE. ASK1 inhibition reduces cell death and hepatic fibrosis in an Nlrp3 mutant liver injury model. JCI Insight 2020;5:123294. [PMID: 31996485 DOI: 10.1172/jci.insight.123294] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 15.0] [Reference Citation Analysis]
209 Karlas T, Blank V, Böhlig A. Diagnostic Value of Ultrasound in Fatty Liver Disease. Ultraschall Med 2021;42:128-53. [PMID: 33622003 DOI: 10.1055/a-1352-4313] [Reference Citation Analysis]
210 Pirola CJ, Sookoian S. Editorial: surviving your genes-the role of PNPLA3 variation in end-stage liver disease. Aliment Pharmacol Ther 2018;48:773-5. [PMID: 30246305 DOI: 10.1111/apt.14901] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
211 Rowe IA. Decision making for liver biopsy in NASH, not so FAST? Lancet Gastroenterol Hepatol 2020;5:332-4. [PMID: 32027859 DOI: 10.1016/S2468-1253(19)30406-6] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
212 Ogawa Y, Yoneda M, Kobayashi T, Honda Y, Kessoku T, Imajo K, Saito S, Nakajima A. Present and emerging pharmacotherapies for non-alcoholic steatohepatitis in adults. Expert Opinion on Pharmacotherapy 2018;20:69-82. [DOI: 10.1080/14656566.2018.1543403] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
213 Kim DY, Park JY. Overview of emerging treatment of non-alcoholic fatty liver disease: more than one drug needed? Hepatobiliary Surg Nutr 2019;8:522-4. [PMID: 31673545 DOI: 10.21037/hbsn.2019.05.08] [Reference Citation Analysis]
214 Hatton G, Alterio T, Nobili V, Mann JP. Unmet needs in pediatric NAFLD research: what do we need to prioritize for the future? Expert Review of Gastroenterology & Hepatology 2018;12:961-7. [DOI: 10.1080/17474124.2018.1512853] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
215 Simon TG, Roelstraete B, Khalili H, Hagström H, Ludvigsson JF. Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort. Gut 2021;70:1375-82. [PMID: 33037056 DOI: 10.1136/gutjnl-2020-322786] [Cited by in Crossref: 15] [Cited by in F6Publishing: 21] [Article Influence: 15.0] [Reference Citation Analysis]
216 Simon TG, Duberg AS, Aleman S, Chung RT, Chan AT, Ludvigsson JF. Association of Aspirin with Hepatocellular Carcinoma and Liver-Related Mortality. N Engl J Med 2020;382:1018-28. [PMID: 32160663 DOI: 10.1056/NEJMoa1912035] [Cited by in Crossref: 54] [Cited by in F6Publishing: 22] [Article Influence: 54.0] [Reference Citation Analysis]
217 Männistö VT, Salomaa V, Färkkilä M, Jula A, Männistö S, Erlund I, Sundvall J, Lundqvist A, Perola M, Åberg F. Incidence of liver-related morbidity and mortality in a population cohort of non-alcoholic fatty liver disease. Liver Int 2021. [PMID: 34219352 DOI: 10.1111/liv.15004] [Reference Citation Analysis]
218 Yilmaz Y, Byrne CD, Musso G. A single-letter change in an acronym: signals, reasons, promises, challenges, and steps ahead for moving from NAFLD to MAFLD. Expert Rev Gastroenterol Hepatol 2021;15:345-52. [PMID: 33270482 DOI: 10.1080/17474124.2021.1860019] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 11.0] [Reference Citation Analysis]
219 Gough NR, Xiang X, Mishra L. TGF-β Signaling in Liver, Pancreas, and Gastrointestinal Diseases and Cancer. Gastroenterology 2021;161:434-452.e15. [PMID: 33940008 DOI: 10.1053/j.gastro.2021.04.064] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
220 Maurice JB, Goldin R, Hall A, Price JC, Sebastiani G, Morse CG, Prat L, Perazzo H, Garvey L, Ingiliz P, Guaraldi G, Tsochatzis E, Lemoine M. Increased BMI and Type 2 diabetes are the main predictors of NAFLD and advanced fibrosis in liver biopsies of patients with HIV mono-infection. Clin Infect Dis 2020:ciaa1302. [PMID: 32877569 DOI: 10.1093/cid/ciaa1302] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
221 Hyun J, Jung Y. DNA Methylation in Nonalcoholic Fatty Liver Disease. Int J Mol Sci 2020;21:E8138. [PMID: 33143364 DOI: 10.3390/ijms21218138] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 9.0] [Reference Citation Analysis]
222 Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018;24:908-922. [PMID: 29967350 DOI: 10.1038/s41591-018-0104-9] [Cited by in Crossref: 777] [Cited by in F6Publishing: 758] [Article Influence: 259.0] [Reference Citation Analysis]
223 Khurana S, Butt W, Khara HS, Johal AS, West SF, Chen ZE, Berger AL, Diehl DL. Bi-lobar liver biopsy via EUS enhances the assessment of disease severity in patients with non-alcoholic steatohepatitis. Hepatol Int 2019;13:323-9. [DOI: 10.1007/s12072-019-09945-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
224 Kuwashiro T, Takahashi H, Hyogo H, Ogawa Y, Imajo K, Yoneda M, Nakahara T, Oeda S, Tanaka K, Amano Y, Ogawa S, Kawaguchi A, Aishima S, Kage M, Chayama K, Nakajima A, Eguchi Y. Discordant pathological diagnosis of non-alcoholic fatty liver disease: A prospective multicenter study. JGH Open 2020;4:497-502. [PMID: 32514460 DOI: 10.1002/jgh3.12289] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
225 Funuyet-Salas J, Pérez-San-Gregorio MÁ, Martín-Rodríguez A, Romero-Gómez M. Psychological Biomarkers and Fibrosis: An Innovative Approach to Non-alcoholic Fatty Liver Disease. Front Med (Lausanne) 2020;7:585425. [PMID: 33195340 DOI: 10.3389/fmed.2020.585425] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
226 Linge J, Borga M, West J, Tuthill T, Miller MR, Dumitriu A, Thomas EL, Romu T, Tunón P, Bell JD, Dahlqvist Leinhard O. Body Composition Profiling in the UK Biobank Imaging Study. Obesity (Silver Spring) 2018;26:1785-95. [PMID: 29785727 DOI: 10.1002/oby.22210] [Cited by in Crossref: 45] [Cited by in F6Publishing: 39] [Article Influence: 15.0] [Reference Citation Analysis]
227 Grgurevic I, Podrug K, Mikolasevic I, Kukla M, Madir A, Tsochatzis EA. Natural History of Nonalcoholic Fatty Liver Disease: Implications for Clinical Practice and an Individualized Approach. Can J Gastroenterol Hepatol 2020;2020:9181368. [PMID: 32051820 DOI: 10.1155/2020/9181368] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 12.0] [Reference Citation Analysis]
228 Shaheen AA, Riazi K, Medellin A, Bhayana D, Kaplan GG, Jiang J, Park R, Schaufert W, Burak KW, Sargious M, Swain MG. Risk stratification of patients with nonalcoholic fatty liver disease using a case identification pathway in primary care: a cross-sectional study. CMAJ Open 2020;8:E370-6. [PMID: 32414883 DOI: 10.9778/cmajo.20200009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
229 Shaheen AA, Swain MG. Editorial: choosing an appropriate risk stratification tool for nonalcoholic fatty liver disease-one size does not fit all. Aliment Pharmacol Ther 2020;51:661-2. [PMID: 32100347 DOI: 10.1111/apt.15640] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
230 Shi T, Wu L, Ma W, Ju L, Bai M, Chen X, Liu S, Yang X, Shi J. Nonalcoholic Fatty Liver Disease: Pathogenesis and Treatment in Traditional Chinese Medicine and Western Medicine. Evid Based Complement Alternat Med 2020;2020:8749564. [PMID: 31998400 DOI: 10.1155/2020/8749564] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 13.0] [Reference Citation Analysis]
231 Hui ST, Wang F, Stappenbeck F, French SW, Magyar CE, Parhami F, Lusis AJ. Oxy210, a novel inhibitor of hedgehog and TGF-β signalling, ameliorates hepatic fibrosis and hypercholesterolemia in mice. Endocrinol Diabetes Metab 2021;4:e00296. [PMID: 34505423 DOI: 10.1002/edm2.296] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
232 Hagström H, Nasr P, Ekstedt M, Hammar U, Stål P, Askling J, Hultcrantz R, Kechagias S. Cardiovascular risk factors in non-alcoholic fatty liver disease. Liver Int 2019;39:197-204. [DOI: 10.1111/liv.13973] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 12.0] [Reference Citation Analysis]
233 Esteban JPG, Asgharpour A. Pharmacologic Treatment Strategies for Nonalcoholic Steatohepatitis. Gastroenterol Clin North Am. 2020;49:105-121. [PMID: 32033758 DOI: 10.1016/j.gtc.2019.10.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
234 Zhang X, Wong VW, Yip TC, Tse YK, Liang LY, Hui VW, Li GL, Chan HL, Wong GL. Colonoscopy and Risk of Colorectal Cancer in Patients With Nonalcoholic Fatty Liver Disease: A Retrospective Territory-Wide Cohort Study. Hepatol Commun 2021;5:1212-23. [PMID: 34278170 DOI: 10.1002/hep4.1705] [Reference Citation Analysis]
235 Eddowes PJ, Mcdonald N, Davies N, Semple SIK, Kendall TJ, Hodson J, Newsome PN, Flintham RB, Wesolowski R, Blake L, Duarte RV, Kelly CJ, Herlihy AH, Kelly MD, Olliff SP, Hübscher SG, Fallowfield JA, Hirschfield GM. Utility and cost evaluation of multiparametric magnetic resonance imaging for the assessment of non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2018;47:631-44. [DOI: 10.1111/apt.14469] [Cited by in Crossref: 44] [Cited by in F6Publishing: 37] [Article Influence: 11.0] [Reference Citation Analysis]
236 Campos-Murguía A, Ruiz-Margáin A, González-Regueiro JA, Macías-Rodríguez RU. Clinical assessment and management of liver fibrosis in non-alcoholic fatty liver disease. World J Gastroenterol 2020; 26(39): 5919-5943 [PMID: 33132645 DOI: 10.3748/wjg.v26.i39.5919] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
237 Soon G, Wee A. Updates in the quantitative assessment of liver fibrosis for nonalcoholic fatty liver disease: Histological perspective. Clin Mol Hepatol 2021;27:44-57. [PMID: 33207115 DOI: 10.3350/cmh.2020.0181] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
238 Gerhardt F, Petroff D, Blank V, Böhlig A, van Bömmel F, Wittekind C, Berg T, Karlas T, Wiegand J. Biopsy rate and nonalcoholic steatohepatitis (NASH) in patients with nonalcoholic fatty liver disease (NAFLD). Scand J Gastroenterol 2020;55:706-11. [PMID: 32476514 DOI: 10.1080/00365521.2020.1766554] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
239 Grgurevic I, Salkic N, Mustapic S, Bokun T, Podrug K, Marusic S, Rahelic D, Matic T, Skurla V, Mikolasevic I. Liver and Nonliver-Related Outcomes at 2 Years Are Not Influenced by the Results of the FIB-4 Test and Liver Elastography in a Real-Life Cohort of Patients with Type 2 Diabetes. Can J Gastroenterol Hepatol 2021;2021:5582813. [PMID: 33763391 DOI: 10.1155/2021/5582813] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
240 Karsdal MA, Detlefsen S, Daniels SJ, Nielsen MJ, Krag A, Schuppan D. Is the Total Amount as Important as Localization and Type of Collagen in Liver Fibrosis Attributable to Steatohepatitis? Hepatology 2020;71:346-51. [PMID: 31553813 DOI: 10.1002/hep.30969] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 6.5] [Reference Citation Analysis]
241 Åberg F, Danford CJ, Thiele M, Talbäck M, Rasmussen DN, Jiang ZG, Hammar N, Nasr P, Ekstedt M, But A, Puukka P, Krag A, Sundvall J, Erlund I, Salomaa V, Stål P, Kechagias S, Hultcrantz R, Lai M, Afdhal N, Jula A, Männistö S, Lundqvist A, Perola M, Färkkilä M, Hagström H. A Dynamic Aspartate-to-Alanine Aminotransferase Ratio Provides Valid Predictions of Incident Severe Liver Disease. Hepatol Commun 2021;5:1021-35. [PMID: 34141987 DOI: 10.1002/hep4.1700] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
242 Kang SH, Lee HW, Yoo JJ, Cho Y, Kim SU, Lee TH, Jang BK, Kim SG, Ahn SB, Kim H, Jun DW, Choi JI, Song DS, Kim W, Jeong SW, Kim MY, Koh H, Jeong S, Lee JW, Cho YK; Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease. Clin Mol Hepatol 2021;27:363-401. [PMID: 34154309 DOI: 10.3350/cmh.2021.0178] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
243 Blank V, Petroff D, Beer S, Böhlig A, Heni M, Berg T, Bausback Y, Dietrich A, Tönjes A, Hollenbach M, Blüher M, Keim V, Wiegand J, Karlas T. Current NAFLD guidelines for risk stratification in diabetic patients have poor diagnostic discrimination.Sci Rep. 2020;10:18345. [PMID: 33110165 DOI: 10.1038/s41598-020-75227-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
244 Hagström H, Talbäck M, Andreasson A, Walldius G, Hammar N. Ability of Noninvasive Scoring Systems to Identify Individuals in the Population at Risk for Severe Liver Disease. Gastroenterology 2020;158:200-14. [PMID: 31563624 DOI: 10.1053/j.gastro.2019.09.008] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 16.0] [Reference Citation Analysis]
245 Hagström H, Adams LA, Allen AM, Byrne CD, Chang Y, Grønbaek H, Ismail M, Jepsen P, Kanwal F, Kramer J, Lazarus JV, Long MT, Loomba R, Newsome PN, Rowe IA, Ryu S, Schattenberg JM, Serper M, Sheron N, Simon TG, Tapper EB, Wild S, Wong VW, Yilmaz Y, Zelber-Sagi S, Åberg F. Administrative Coding in Electronic Health Care Record-Based Research of NAFLD: An Expert Panel Consensus Statement. Hepatology 2021;74:474-82. [PMID: 33486773 DOI: 10.1002/hep.31726] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
246 Hagström H, Nasr P, Ekstedt M, Hammar U, Widman L, Stål P, Hultcrantz R, Kechagias S, Henriksson M. Health Care Costs of Patients With Biopsy-Confirmed Nonalcoholic Fatty Liver Disease Are Nearly Twice Those of Matched Controls. Clinical Gastroenterology and Hepatology 2020;18:1592-1599.e8. [DOI: 10.1016/j.cgh.2019.10.023] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
247 Puengel T, De Vos S, Hundertmark J, Kohlhepp M, Guldiken N, Pujuguet P, Auberval M, Marsais F, Shoji KF, Saniere L, Trautwein C, Luedde T, Strnad P, Brys R, Clément-Lacroix P, Tacke F. The Medium-Chain Fatty Acid Receptor GPR84 Mediates Myeloid Cell Infiltration Promoting Steatohepatitis and Fibrosis. J Clin Med 2020;9:E1140. [PMID: 32316235 DOI: 10.3390/jcm9041140] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 15.0] [Reference Citation Analysis]
248 Mao X, Liu Z, Shi O, Yu K, Jiang Y, Jin L, Zhang T, Chen X. Non-invasive fibrosis markers are associated with mortality risk in both general populations and non-alcoholic fatty liver disease patients. Hepatol Res 2021;51:90-101. [PMID: 32946623 DOI: 10.1111/hepr.13570] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
249 Pais R, Maurel T. Natural History of NAFLD. J Clin Med 2021;10:1161. [PMID: 33802047 DOI: 10.3390/jcm10061161] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
250 Ekstedt M, Nasr P, Kechagias S. Natural History of NAFLD/NASH. Curr Hepatol Rep. 2017;16:391-397. [PMID: 29984130 DOI: 10.1007/s11901-017-0378-2] [Cited by in Crossref: 51] [Cited by in F6Publishing: 53] [Article Influence: 12.8] [Reference Citation Analysis]
251 Kosick HM, Keyrouz A, Adeyi O, Sebastiani G, Patel K. A Stepwise Algorithmic Approach and External Validation Study for Noninvasive Prediction of Advanced Fibrosis in Nonalcoholic Fatty Liver Disease. Dig Dis Sci 2021. [PMID: 33389416 DOI: 10.1007/s10620-020-06748-8] [Reference Citation Analysis]
252 Maurice JB, Garvey L, Tsochatzis EA, Wiltshire M, Cooke G, Guppy N, McDonald J, Marchesi J, Nelson M, Kelleher P, Goldin R, Thursz M, Lemoine M. Monocyte-macrophage activation is associated with nonalcoholic fatty liver disease and liver fibrosis in HIV monoinfection independently of the gut microbiome and bacterial translocation. AIDS 2019;33:805-14. [PMID: 30882489 DOI: 10.1097/QAD.0000000000002133] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 10.0] [Reference Citation Analysis]
253 Hagström H, Nasr P, Ekstedt M, Hammar U, Stål P, Hultcrantz R, Kechagias S. Risk for development of severe liver disease in lean patients with nonalcoholic fatty liver disease: A long-term follow-up study. Hepatol Commun 2018;2:48-57. [PMID: 29404512 DOI: 10.1002/hep4.1124] [Cited by in Crossref: 80] [Cited by in F6Publishing: 79] [Article Influence: 20.0] [Reference Citation Analysis]
254 Adams LA, Roberts SK, Strasser SI, Mahady SE, Powell E, Estes C, Razavi H, George J. Nonalcoholic fatty liver disease burden: Australia, 2019-2030. J Gastroenterol Hepatol. 2020;35:1628-1635. [PMID: 32048317 DOI: 10.1111/jgh.15009] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
255 Sumida Y, Okanoue T, Nakajima A; Japan Study Group of NAFLD (JSG-NAFLD). Phase 3 drug pipelines in the treatment of non-alcoholic steatohepatitis. Hepatol Res 2019;49:1256-62. [PMID: 31495973 DOI: 10.1111/hepr.13425] [Cited by in Crossref: 28] [Cited by in F6Publishing: 32] [Article Influence: 14.0] [Reference Citation Analysis]
256 Majumdar A, Tsochatzis EA. Changing trends of liver transplantation and mortality from non-alcoholic fatty liver disease. Metabolism 2020;111:154291. [DOI: 10.1016/j.metabol.2020.154291] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
257 Newsome P, Francque S, Harrison S, Ratziu V, Van Gaal L, Calanna S, Hansen M, Linder M, Sanyal A. Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity. Aliment Pharmacol Ther 2019;50:193-203. [PMID: 31246368 DOI: 10.1111/apt.15316] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 20.0] [Reference Citation Analysis]
258 Shang Y, Nasr P, Ekstedt M, Widman L, Stål P, Hultcrantz R, Kechagias S, Hagström H. Non-alcoholic fatty liver disease does not increase dementia risk although histology data might improve risk prediction. JHEP Rep 2021;3:100218. [PMID: 33554097 DOI: 10.1016/j.jhepr.2020.100218] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
259 Stefan N. Nonalcoholic Fatty Liver Disease and Mortality. Clin Gastroenterol Hepatol 2018;16:1043-5. [PMID: 29474973 DOI: 10.1016/j.cgh.2018.02.016] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
260 Moore JB. From sugar to liver fat and public health: systems biology driven studies in understanding non-alcoholic fatty liver disease pathogenesis. Proc Nutr Soc. 2019;78:290-304. [PMID: 30924429 DOI: 10.1017/s0029665119000570] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 6.5] [Reference Citation Analysis]
261 Rowe IA. The devotion to surrogate outcomes in drug development for liver disease. Nat Rev Gastroenterol Hepatol 2018;15:1-2. [DOI: 10.1038/nrgastro.2017.155] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
262 Yanavich C, Pacheco AG, Cardoso SW, Nunes EP, Chaves U, Freitas G, Santos R, Morata M, Veloso VG, Grinsztejn B, Perazzo H. Diagnostic value of serological biomarkers for detection of non-alcoholic fatty liver disease (NAFLD) and/or advanced liver fibrosis in people living with HIV. HIV Med 2021;22:445-56. [PMID: 33529485 DOI: 10.1111/hiv.13060] [Reference Citation Analysis]
263 Lupsor-Platon M, Serban T, Silion AI, Tirpe A, Florea M. Hepatocellular Carcinoma and Non-Alcoholic Fatty Liver Disease: A Step Forward for Better Evaluation Using Ultrasound Elastography. Cancers (Basel) 2020;12:E2778. [PMID: 32998257 DOI: 10.3390/cancers12102778] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
264 Vilar-Gomez E, Chalasani N. Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers. J Hepatol. 2018;68:305-315. [PMID: 29154965 DOI: 10.1016/j.jhep.2017.11.013] [Cited by in Crossref: 190] [Cited by in F6Publishing: 178] [Article Influence: 47.5] [Reference Citation Analysis]
265 Hagström H, Bu D, Nasr P, Ekstedt M, Hegmar H, Kechagias S, Zhang N, An Z, Stål P, Scherer PE. Serum levels of endotrophin are associated with nonalcoholic steatohepatitis. Scand J Gastroenterol 2021;56:437-42. [PMID: 33556256 DOI: 10.1080/00365521.2021.1879249] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
266 Majo J, Klinkhammer BM, Boor P, Tiniakos D. Pathology and natural history of organ fibrosis. Curr Opin Pharmacol 2019;49:82-9. [PMID: 31671319 DOI: 10.1016/j.coph.2019.09.009] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
267 Niriella MA, Kasturiratne A, Beddage TU, Withanage SA, Goonatilleke DC, Abeysinghe CP, De Mel RT, Balapitiya TL, De Silva ST, Dassanayake AS, De Silva AP, Pathmeswaran A, Wickramasinghe AR, Kato N, Silva HJ. Metabolic syndrome, but not non‐alcoholic fatty liver disease, increases 10‐year mortality: A prospective, community‐cohort study. Liver Int 2019;40:101-6. [DOI: 10.1111/liv.14237] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
268 Polyzos SA, Kang ES, Boutari C, Rhee E, Mantzoros CS. Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis. Metabolism 2020;111:154203. [DOI: 10.1016/j.metabol.2020.154203] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 35.0] [Reference Citation Analysis]
269 Samji NS, Verma R, Keri KC, Singal AK, Ahmed A, Rinella M, Bernstein D, Abdelmalek MF, Satapathy SK. Liver Transplantation for Nonalcoholic Steatohepatitis: Pathophysiology of Recurrence and Clinical Challenges. Dig Dis Sci 2019;64:3413-30. [PMID: 31312990 DOI: 10.1007/s10620-019-05716-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
270 Vilar-gomez E, Calzadilla-bertot L, Wai-sun Wong V, Castellanos M, Aller-de la Fuente R, Metwally M, Eslam M, Gonzalez-fabian L, Alvarez-quiñones Sanz M, Conde-martin AF, De Boer B, Mcleod D, Hung Chan AW, Chalasani N, George J, Adams LA, Romero-gomez M. Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study. Gastroenterology 2018;155:443-457.e17. [DOI: 10.1053/j.gastro.2018.04.034] [Cited by in Crossref: 235] [Cited by in F6Publishing: 231] [Article Influence: 78.3] [Reference Citation Analysis]
271 Sofias AM, De Lorenzi F, Peña Q, Azadkhah Shalmani A, Vucur M, Wang JW, Kiessling F, Shi Y, Consolino L, Storm G, Lammers T. Therapeutic and diagnostic targeting of fibrosis in metabolic, proliferative and viral disorders. Adv Drug Deliv Rev 2021;175:113831. [PMID: 34139255 DOI: 10.1016/j.addr.2021.113831] [Reference Citation Analysis]
272 Zhou IY, Clavijo Jordan V, Rotile NJ, Akam E, Krishnan S, Arora G, Krishnan H, Slattery H, Warner N, Mercaldo N, Farrar CT, Wellen J, Martinez R, Schlerman F, Tanabe KK, Fuchs BC, Caravan P. Advanced MRI of Liver Fibrosis and Treatment Response in a Rat Model of Nonalcoholic Steatohepatitis. Radiology 2020;296:67-75. [PMID: 32343209 DOI: 10.1148/radiol.2020192118] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
273 Tao MH, Fulda KG. Association of Magnesium Intake with Liver Fibrosis among Adults in the United States. Nutrients 2021;13:E142. [PMID: 33401667 DOI: 10.3390/nu13010142] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
274 Nakatsuka T, Tateishi R, Koike K. Changing clinical management of NAFLD in Asia. Liver Int 2021. [PMID: 34459096 DOI: 10.1111/liv.15046] [Reference Citation Analysis]
275 Patel SS, Siddiqui MS. Current and Emerging Therapies for Non-alcoholic Fatty Liver Disease. Drugs. 2019;79:75-84. [PMID: 30588564 DOI: 10.1007/s40265-018-1040-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
276 Targher G, Byrne CD, Tilg H. NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications. Gut 2021;69:1691-705. [DOI: 10.1136/gutjnl-2020-320622] [Cited by in Crossref: 53] [Cited by in F6Publishing: 59] [Article Influence: 53.0] [Reference Citation Analysis]
277 Younossi ZM, Loomba R, Rinella ME, Bugianesi E, Marchesini G, Neuschwander-Tetri BA, Serfaty L, Negro F, Caldwell SH, Ratziu V, Corey KE, Friedman SL, Abdelmalek MF, Harrison SA, Sanyal AJ, Lavine JE, Mathurin P, Charlton MR, Chalasani NP, Anstee QM, Kowdley KV, George J, Goodman ZD, Lindor K. Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology. 2018;68:361-371. [PMID: 29222911 DOI: 10.1002/hep.29724] [Cited by in Crossref: 161] [Cited by in F6Publishing: 144] [Article Influence: 53.7] [Reference Citation Analysis]
278 Rinella ME, Tacke F, Sanyal AJ, Anstee QM. Report on the AASLD/EASL joint workshop on clinical trial endpoints in NAFLD. Journal of Hepatology 2019;71:823-33. [DOI: 10.1016/j.jhep.2019.04.019] [Cited by in Crossref: 45] [Cited by in F6Publishing: 48] [Article Influence: 22.5] [Reference Citation Analysis]
279 Roh YH, Kang BK, Jun DW, Lee CM, Kim M. Role of FIB-4 for reassessment of hepatic fibrosis burden in referral center. Sci Rep 2021;11:13616. [PMID: 34193951 DOI: 10.1038/s41598-021-93038-6] [Reference Citation Analysis]
280 Xin X, Cai BY, Chen C, Tian HJ, Wang X, Hu YY, Feng Q. High-trans fatty acid and high-sugar diets can cause mice with non-alcoholic steatohepatitis with liver fibrosis and potential pathogenesis. Nutr Metab (Lond) 2020;17:40. [PMID: 32508961 DOI: 10.1186/s12986-020-00462-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
281 De Chiara F, Thomsen KL, Habtesion A, Jones H, Davies N, Gracia-Sancho J, Manicardi N, Hall A, Andreola F, Paish HL, Reed LH, Watson AA, Leslie J, Oakley F, Rombouts K, Mookerjee RP, Mann J, Jalan R. Ammonia Scavenging Prevents Progression of Fibrosis in Experimental Nonalcoholic Fatty Liver Disease. Hepatology 2020;71:874-92. [PMID: 31378982 DOI: 10.1002/hep.30890] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 9.0] [Reference Citation Analysis]
282 Valentino G, Zivko C, Weber F, Brülisauer L, Luciani P. Synergy of Phospholipid-Drug Formulations Significantly Deactivates Profibrogenic Human Hepatic Stellate Cells. Pharmaceutics 2019;11:E676. [PMID: 31842373 DOI: 10.3390/pharmaceutics11120676] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
283 Chakravarthy MV, Neuschwander-Tetri BA. The metabolic basis of nonalcoholic steatohepatitis. Endocrinol Diabetes Metab 2020;3:e00112. [PMID: 33102794 DOI: 10.1002/edm2.112] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 14.0] [Reference Citation Analysis]
284 Stefan N, Häring H, Cusi K. Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies. The Lancet Diabetes & Endocrinology 2019;7:313-24. [DOI: 10.1016/s2213-8587(18)30154-2] [Cited by in Crossref: 220] [Cited by in F6Publishing: 115] [Article Influence: 110.0] [Reference Citation Analysis]
285 Lazarus JV, Anstee QM, Hagström H, Cusi K, Cortez-Pinto H, Mark HE, Roden M, Tsochatzis EA, Wong VW, Younossi ZM, Zelber-Sagi S, Romero-Gómez M, Schattenberg JM. Defining comprehensive models of care for NAFLD. Nat Rev Gastroenterol Hepatol 2021. [PMID: 34172937 DOI: 10.1038/s41575-021-00477-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
286 Thiagarajan P, Aithal GP. Drug Development for Nonalcoholic Fatty Liver Disease: Landscape and Challenges. J Clin Exp Hepatol 2019;9:515-21. [PMID: 31516268 DOI: 10.1016/j.jceh.2019.03.002] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 5.5] [Reference Citation Analysis]
287 Axley P, Mudumbi S, Sarker S, Kuo YF, Singal AK. Patients with stage 3 compared to stage 4 liver fibrosis have lower frequency of and longer time to liver disease complications. PLoS One 2018;13:e0197117. [PMID: 29746540 DOI: 10.1371/journal.pone.0197117] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
288 Cohen CC, Castillo-Leon E, Farris AB, Caltharp SA, Cleeton RL, Sinclair EM, Shevell DE, Karsdal MA, Nielsen MJF, Leeming DJ, Vos MB. PRO-C3, a Serological Marker of Fibrosis, During Childhood and Correlations With Fibrosis in Pediatric NAFLD. Hepatol Commun 2021;5:1860-72. [PMID: 34558828 DOI: 10.1002/hep4.1766] [Reference Citation Analysis]
289 Li X, Wang TX, Huang X, Li Y, Sun T, Zang S, Guan KL, Xiong Y, Liu J, Yuan HX. Targeting ferroptosis alleviates methionine-choline deficient (MCD)-diet induced NASH by suppressing liver lipotoxicity. Liver Int 2020;40:1378-94. [PMID: 32145145 DOI: 10.1111/liv.14428] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 14.0] [Reference Citation Analysis]
290 Tutusaus A, de Gregorio E, Cucarull B, Cristóbal H, Aresté C, Graupera I, Coll M, Colell A, Gausdal G, Lorens JB, García de Frutos P, Morales A, Marí M. A Functional Role of GAS6/TAM in Nonalcoholic Steatohepatitis Progression Implicates AXL as Therapeutic Target. Cell Mol Gastroenterol Hepatol 2020;9:349-68. [PMID: 31689560 DOI: 10.1016/j.jcmgh.2019.10.010] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
291 Bauvin P, Delacôte C, Lassailly G, Ntandja Wandji LC, Gnemmi V, Dautrecque F, Louvet A, Caiazzo R, Raverdy V, Leteurtre E, Pattou F, Deuffic-Burban S, Mathurin P. A tool to predict progression of non-alcoholic fatty liver disease in severely obese patients. Liver Int 2021;41:91-100. [PMID: 32881244 DOI: 10.1111/liv.14650] [Reference Citation Analysis]
292 Fourman LT, Stanley TL, Zheng I, Pan CS, Feldpausch MN, Purdy J, Aepfelbacher J, Buckless C, Tsao A, Corey KE, Chung RT, Torriani M, Kleiner DE, Hadigan CM, Grinspoon SK. Clinical Predictors of Liver Fibrosis Presence and Progression in Human Immunodeficiency Virus-Associated Nonalcoholic Fatty Liver Disease. Clin Infect Dis 2021;72:2087-94. [PMID: 32270862 DOI: 10.1093/cid/ciaa382] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
293 Mosca A, Comparcola D, Romito I, Mantovani A, Nobili V, Byrne CD, Alisi A, Targher G. Plasma N-terminal propeptide of type III procollagen accurately predicts liver fibrosis severity in children with non-alcoholic fatty liver disease. Liver Int. 2019;39:2317-2329. [PMID: 31436362 DOI: 10.1111/liv.14225] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
294 Arab JP, Dirchwolf M, Álvares-da-Silva MR, Barrera F, Benítez C, Castellanos-Fernandez M, Castro-Narro G, Chavez-Tapia N, Chiodi D, Cotrim H, Cusi K, de Oliveira CPMS, Díaz J, Fassio E, Gerona S, Girala M, Hernandez N, Marciano S, Masson W, Méndez-Sánchez N, Leite N, Lozano A, Padilla M, Panduro A, Paraná R, Parise E, Perez M, Poniachik J, Restrepo JC, Ruf A, Silva M, Tagle M, Tapias M, Torres K, Vilar-Gomez E, Costa Gil JE, Gadano A, Arrese M. Latin American Association for the study of the liver (ALEH) practice guidance for the diagnosis and treatment of non-alcoholic fatty liver disease.Ann Hepatol. 2020;19:674-690. [PMID: 33031970 DOI: 10.1016/j.aohep.2020.09.006] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
295 Tsuchiya A, Takeuchi S, Watanabe T, Yoshida T, Nojiri S, Ogawa M, Terai S. Mesenchymal stem cell therapies for liver cirrhosis: MSCs as "conducting cells" for improvement of liver fibrosis and regeneration. Inflamm Regen. 2019;39:18. [PMID: 31516638 DOI: 10.1186/s41232-019-0107-z] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 12.5] [Reference Citation Analysis]
296 Sanyal AJ, Harrison SA, Ratziu V, Abdelmalek MF, Diehl AM, Caldwell S, Shiffman ML, Aguilar Schall R, Jia C, McColgan B, Djedjos CS, McHutchison JG, Subramanian GM, Myers RP, Younossi Z, Muir AJ, Afdhal NH, Bosch J, Goodman Z. The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials. Hepatology. 2019;70:1913-1927. [PMID: 30993748 DOI: 10.1002/hep.30664] [Cited by in Crossref: 75] [Cited by in F6Publishing: 82] [Article Influence: 37.5] [Reference Citation Analysis]
297 Crouchet E, Bandiera S, Fujiwara N, Li S, El Saghire H, Fernández-Vaquero M, Riedl T, Sun X, Hirschfield H, Jühling F, Zhu S, Roehlen N, Ponsolles C, Heydmann L, Saviano A, Qian T, Venkatesh A, Lupberger J, Verrier ER, Sojoodi M, Oudot MA, Duong FHT, Masia R, Wei L, Thumann C, Durand SC, González-Motos V, Heide D, Hetzer J, Nakagawa S, Ono A, Song WM, Higashi T, Sanchez R, Kim RS, Bian CB, Kiani K, Croonenborghs T, Subramanian A, Chung RT, Straub BK, Schuppan D, Ankavay M, Cocquerel L, Schaeffer E, Goossens N, Koh AP, Mahajan M, Nair VD, Gunasekaran G, Schwartz ME, Bardeesy N, Shalek AK, Rozenblatt-Rosen O, Regev A, Felli E, Pessaux P, Tanabe KK, Heikenwälder M, Schuster C, Pochet N, Zeisel MB, Fuchs BC, Hoshida Y, Baumert TF. A human liver cell-based system modeling a clinical prognostic liver signature for therapeutic discovery. Nat Commun 2021;12:5525. [PMID: 34535664 DOI: 10.1038/s41467-021-25468-9] [Reference Citation Analysis]
298 Akazawa Y, Nakashima R, Matsuda K, Okamaoto K, Hirano R, Kawasaki H, Miuma S, Miyaaki H, Malhi H, Abiru S, Itoh M, Kondo H, Fukuoka J, Nakao K, Nakashima M. Detection of DNA damage response in nonalcoholic fatty liver disease via p53-binding protein 1 nuclear expression. Mod Pathol 2019;32:997-1007. [PMID: 30809000 DOI: 10.1038/s41379-019-0218-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
299 Marcher AB, Bendixen SM, Terkelsen MK, Hohmann SS, Hansen MH, Larsen BD, Mandrup S, Dimke H, Detlefsen S, Ravnskjaer K. Transcriptional regulation of Hepatic Stellate Cell activation in NASH. Sci Rep 2019;9:2324. [PMID: 30787418 DOI: 10.1038/s41598-019-39112-6] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 13.5] [Reference Citation Analysis]
300 Donnellan E, Cotter TG, Wazni OM, Elshazly MB, Kochar A, Wilner B, Patel D, Kanj M, Hussein A, Baranowski B, Cantillon D, Griffin B, Jaber W, Saliba WI. Impact of Nonalcoholic Fatty Liver Disease on Arrhythmia Recurrence Following Atrial Fibrillation Ablation. JACC Clin Electrophysiol 2020;6:1278-87. [PMID: 33092755 DOI: 10.1016/j.jacep.2020.05.023] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
301 Lee JI, Lee HW, Lee KS. Value of controlled attenuation parameter in fibrosis prediction in nonalcoholic steatohepatitis. World J Gastroenterol 2019; 25(33): 4959-4969 [PMID: 31543686 DOI: 10.3748/wjg.v25.i33.4959] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
302 Albracht-Schulte K, Rosairo S, Ramalingam L, Wijetunge S, Ratnayake R, Kotakadeniya H, Dawson JA, Kalupahana NS, Moustaid-Moussa N. Obesity, adipocyte hypertrophy, fasting glucose, and resistin are potential contributors to nonalcoholic fatty liver disease in South Asian women. Diabetes Metab Syndr Obes. 2019;12:863-872. [PMID: 31354322 DOI: 10.2147/dmso.s203937] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
303 Karlas T. Diagnose und Verlaufsbeurteilung von Fettlebererkrankungen: Relevanz sonographischer Verfahren. Gastroenterologe 2018;13:272-83. [DOI: 10.1007/s11377-018-0263-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
304 Pal P, Palui R, Ray S. Heterogeneity of non-alcoholic fatty liver disease: Implications for clinical practice and research activity. World J Hepatol 2021; 13(11): 1584-1610 [DOI: 10.4254/wjh.v13.i11.1584] [Reference Citation Analysis]
305 Mann JP, Carter P, Armstrong MJ, Abdelaziz HK, Uppal H, Patel B, Chandran S, More R, Newsome PN, Potluri R. Hospital admission with non-alcoholic fatty liver disease is associated with increased all-cause mortality independent of cardiovascular risk factors. PLoS One. 2020;15:e0241357. [PMID: 33108366 DOI: 10.1371/journal.pone.0241357] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
306 Gill MG, Majumdar A. Metabolic associated fatty liver disease: Addressing a new era in liver transplantation. World J Hepatol 2020; 12(12): 1168-1181 [PMID: 33442446 DOI: 10.4254/wjh.v12.i12.1168] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
307 Francque S, Szabo G, Abdelmalek MF, Byrne CD, Cusi K, Dufour J, Roden M, Sacks F, Tacke F. Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors. Nat Rev Gastroenterol Hepatol 2021;18:24-39. [DOI: 10.1038/s41575-020-00366-5] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 22.0] [Reference Citation Analysis]
308 Rowe IA. Histological Endpoints for Nonalcoholic Steatohepatitis Trials: Lights and Shadows. Semin Liver Dis 2020;40:339-45. [PMID: 32906165 DOI: 10.1055/s-0040-1709491] [Reference Citation Analysis]
309 Marjot T, Moolla A, Cobbold JF, Hodson L, Tomlinson JW. Nonalcoholic Fatty Liver Disease in Adults: Current Concepts in Etiology, Outcomes, and Management. Endocr Rev. 2020;41. [PMID: 31629366 DOI: 10.1210/endrev/bnz009] [Cited by in Crossref: 30] [Cited by in F6Publishing: 35] [Article Influence: 30.0] [Reference Citation Analysis]